
MFT TRUST FORMULARY



	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 10.7 (July 2025)



Prescribers must always bear in mind when prescribing medicines recommended as " treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



GMMMG Red/Amber/Green classifications



RED

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

AMBER

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP).

See here for a list of GMMMG approved SCPs.

GREEN

Drugs that are suitable for initiation and ongoing prescribing within primary care.

SA

Green following specialist advice. Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

SI

Green following specialist initiation. Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

(DNP)

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

GREY

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

отс

In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care.



Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be annotated as follows: drug name

Formulary symbols

MMC	Medicines Management Committee decisions
emc⊚	Electronic medicines compendium (SmPC & PIL)
BNF	British National Formulary (BNF)
BNF for children	British National Formulary for Children (BNFC)
NICE	NICE guidance
PbR X	NHS Payment Scheme (NHSPS) excluded medicine (previously known as PbR excluded)
<u>ca</u>	Controlled Drug
0	Unlicensed medicine
££	High cost medicine
blueteq	Blueteq enabled forms
MedTeq	MedTeq Enabled Forms
NOT STOCKED	Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY

 G_{MMM}

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (No password required)

British National Formulary for Children (No password required)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal system

Supported by the formulary (click here)



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics Other Antispasmodics Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Faecal Incontinence (CG49)

Irritable Bowel Syndrome (CG61)

Diarrhoea and vomiting in children under 5 (CG84)

Constipation in children and young people (CG99)

Acute upper GI bleeding (CG141)

Dyspepsia and gastro-oesophageal reflux disease (CG184)

Coeliac disease: recognition, assessment and management (NG20)

Crohn's disease: management (NG129)
Ulcerative colitis: management (NG130)

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

Crohn's disease - infliximab & adalimumab (TA187)

Constipation (women) - prucalopride (TA211)

Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Naloxegol for treating opioid induced constipation (TA345)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Obeticholic acid for treating primary biliary cholangitis (TA443)

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

Naldemedine for treating opioid-induced constipation (TA651)

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

Teduglutide for treating short bowel syndrome (TA804)

Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

Elafibranor for previously treated primary biliary cholangitis (TA1016)

Mirikizumab for treating moderately to severely active Crohn's disease (TA1080)


GMMMG Formulary


Formulary Homepage


Chapter 1: Gastro-Intestinal system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List












Alicaforsen U			RESTRICTED
E£		SINIF for shilldren	Gastro. Consultants only - pouchitis
enema	PbR X	MMC BNF emc	
		· ·	


PBRX NICE MMC BNF emco


infusion

ICAM-1 Inhibitor









1.10 Miscellaneous preparations Glucarpidase RED (I) Voraxaze ® 1,000 unit injection (see also sections 8.4, 10.4 & 13.14) PDRX MMC (BNF) emc®

Non-Formulary Items Darvadstrocel (DNP) REJECTED in line of NICE TA556	
The state of the s	
	with
NICE TASSO	
Diarrhoea (adults)	
in line with GMMMG /	NHSE
Dicycloverine hydrochloride (DNP) in line with GMMN	1G
BNF emc Criterion 2	
Haemorrhoids (DNP) in line with GMMMG /	NHSE
Indigestion and heartburn (DNP) in line with GMMMG /	NHSE
Infant colic (DNP) in line with GMMMG /	NHSE
Infrequent constipation (duration less than 2 weeks) (DNP) in line with GMMMG /	NHSE
IQoro (DNP) in line with GMMN	1G
Neuromuscular training device Criterion 1	
Lactase drops (DNP) in line with GMMN	IG
e.g Colief® Criterion 1	
Lubiprostone Discontinued Jan-	-19
capsules NICE MMC emc	
Macrogols Discontinued Apr- Klean-Prep® oral powder MMC BNF €mc⊛	-24
OTC haemorrhoid preparations (DNP) in line with GMMN	1G
NICE BNF emco	
Racecadotril in line with GMMN	1G
capsules; granules for oral suspension; tablets Criterion 1	
Rifaximin in line with GMMMG for T diarrhoea	raveller's
200mg tablets (see also section 5.1.7)	
Stoma deodorant sprays [DNP] in line with GMMN	IG
Criterion 3	
VSL#3® / Vivomixx® food supplement (DNP) in line with GMMN	IG
Criterion 1	

Section 2: Cardiovascular system

Supported by the formulary (click here)



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

2.10.2 Fibrinolytic Drugs

- 2.11 Antifibrinolytic drugs & haemostatics
- 2.12 Lipid-regulating drugs
- 2.13 Local sclerosants
- 2.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)

CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Familial hypercholesterolaemia (CG71)

Chest pain of recent onset (CG95)

Stable angina (CG126)

Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

Chronic heart failure in adults: diagnosis and management (NG106)

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

Hypertension in pregnancy: diagnosis and management (NG133)

Hypertension in adults: diagnosis and management (NG136)

Acute coronary syndromes (NG185)

Atrial fibrillation: diagnosis and management (NG196)

Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

Acute coronary syndromes - glycoprotein Ilb/IIIa inhibitors (review) (TA47)

Myocardial infarction - thrombolysis (TA52)

Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)

Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated bt TA95 & TA126)

Hypercholesterolaemia - Ezetimibe (TA132)

Coronary artery disease - drug eleuting stents (TA152)

Venous thromboembolism - dabigatran (TA157)

Rivaroxaban for the prevention of VTE (TA170)

Atrial Fibrillation - dronedarone (TA197)

Vascular disease - clopidogrel and dipyridamole (TA210)

Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)

Acute coronary syndromes - ticagrelor (TA236)

Venous thromboembolism - apixaban (hip and knee surgery) (TA245)

Atrial fibrillation - dabigatran etexilate (TA249)

Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)

Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)

Stroke (acute, ischaemic) - alteplase (TA264)

Chronic heart failure - ivabradine (TA267)

Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)

Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)

Prasugrel with PCI for treating ACS (review of TA182) (TA317)

Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

Tenecteplase for treating acute ischaemic stroke (TA990)

Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)


GMMMG Formulary


Formulary Homepage


Chapter 2: Cardiovascular system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List








2.4 Beta-adrenoceptor blocking dru	ugs	GMMG
		NICE NG106
		NICE NG136
2.4 Beta-Adrenoceptor Blocking Drugs		NICE NG196
Atenolol		
GREEN	SNF	
tablets; liquid; injection	BNF emco	
Bisoprolol fumarate		RESTRICTED adults.
GREEN		Cardiology Consultant only
tablets	MMC BNF emco	
Carvedilol		RESTRICTED adults.
GREEN	RINIE	Cardiology Consultant only
tablets	MMC BNF emco	ALSO 2ND LINE FOR VARICEAL BLEED
Esmolol hydrochloride	WIW BNF GIICS	RESTRICTED
	FeYNW-	I.V. only
injection	EXPORT IN CONTRACT OF THE CONT	Siny
injection Etilefrine hydrochloride U	BNF emc	DESTRUCTED Has models my
Etherine nydrocinoride		RESTRICTED Haematology Consultants - SCD
		Consultants - SCD
tablets	MMC	
Labetalol hydrochloride GREEN		RESTRICTED
GREEN	BONUE Descriptions	oral preps in pregnancy
tablets; injection	BNF emco	
Metoprolol tartrate		
	BINDE	
tablets; injection	BNF emc	
Nadolol		RESTRICTED paeds. ventricular
		arrhythmias in long QT syndrome
tablets	MMC BNF emco	
Nebivolol		
tablets	BNF emc	
Propranolol hydrochloride	Silico	RESTRICTED
GREEN	PINE	not in Cardiology
tablets; capsules; oral solution; injection	MMC BNF emc	
Sotalol hydrochloride	MIMIC BRIF EITICO	
oomoi nyaroomoino		
	SANTE to a shift has	
tablets	BNF emc	




2mg; 4mg & 8mg tablets

MMC BNF emc

2.5.5.2 Angiotensin-II Receptor Antagonists		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angioten	sin system drugs in heart failure: risk of potentially fatal hyperl	kalaemia
Candesartan cilexetil GREEN	SRI	1 st line use hypertension
2mg; 4mg; 8mg; 16mg & 32mg tablets	MMC BNF emc	GM <mark>™</mark> MG
Losartan potassium GREEN		2 nd line use hypertension
12.5mg; 25mg; 50mg & 100mg tablets	BNF emc	
Irbesartan GREEN		2 nd line use hypertension
75mg;150mg & 300mg tablets	MMC BNF emc	
Valsartan		2 nd line use
GREEN		hypertension
40mg;80mg & 160mg capsules	MMC BNF emc	
Sacubitril / Valsartan	SME	RESTRICTED use in line with NICE TA388
24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets	NICE MMC BNF emco	
2.5.5.3 Renin inhibitors		
Aliskiren (DNP)		RESTRICTED adults. Specialist initiation only
150mg; 300mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardio		
2.5.5.4 Heart Failure		
Dapagliflozin		RESTRICTED adults.
SA Sanita @ tablete	AAAAO TITO AAAAO	Specialist initiation in line with TA679
Forxiga ® tablets	NICE MMC BNF (emco)	
Empagliflozin SA		RESTRICTED adults. Specialist initiation in line with TA773
Jardiance ® tablets	NICE MMC BNF @mc	




2.7 Sympathomimetics		G⋈ <mark>M</mark> MG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED 1. V.
		Specialist use only
nfusion	BNF emc	
Dopamine hydrochloride		RESTRICTED 1. V.
		Specialist use only
fusion	BNF emc	
Dopexamine		RESTRICTED 1. V.
		Specialist use only
nfusion	BNF emc	
soprenaline		RESTRICTED /. V.
		Specialist use only
njection	BNF emc	
2.7.2 Vasoconstrictor Sympathomimetics		
Adrenaline acid tartrate 🏻 🕛		Specialist use endoscopic sinus
	BALF	surgery
in 1000 (0.1%w/v) cutaneous solution)	MMC BNF emc	
Ephedrine hydrochloride		RESTRICTED I.V.
		Specialist use only
njection	BNF emc	
Metaraminol ^①	<u></u>	
njection	BNF emco	
Midodrine	<u>Gines</u>	Specialist use Cardiology /
SI		Healthcare of the elderly
ablets	MMC BNF emc	
Voradrenaline acid tartrate	minio Chico	RESTRICTED /. V.
	SIN S	Specialist use only
nfusion	BNF emco	
Phenylephrine hydrochloride	BNP	RESTRICTED /. V.
• • • • • • • • • • • • • • • • • • • •	RINE -	Specialist use only
njection	BNF emco	
2.7.3 Cardiopulmonary Resuscitation	BNP	
Adrenaline / Epinephrine		
GREEN	and the same of th	
plaction	Total district	
njection	BNF emc	





© Manchester University NHS Foundation Trust 2025






2.10 Stable angina, ACS & fibrinolysis		GM <mark>™</mark> MG
Stable angina (BNF treatment summary)		
Acute coronary syndromes (BNF treatment summary)		
Fibrinolytic Drugs (BNF treatment summary)		NICE CG126
2.10.2 Fibrinolytic Drugs		NICE NG128
Tenecteplase RED		
injection	NICE MMC BNF	ome
Streptokinase		ence
RED		
infusion	NICE BNF	emco
Urokinase		
RED		
injection	BNF	emc
Alteplase		DESTRICTED
RED		RESTRICTED
injection; infusion	NICE MMC BNF	emc _®






Alirocumab			RESTRICTED adults. Lipid Clinic
RED			Consultants in line with TA393
Praluent® injection	- MANO		Concurrence in time with 1710cc
Bempedoic acid (see also <i>Nustendi</i> ®)	PBRX NICE MMC BNF	emc	DESTRUCTED III O III I
GREEN (See also Nusterial (S)			RESTRICTED adults. Consultants in line with TA694
Nilemdo ® tablets	PBRX NICE MMC BNF	emc⊕	
Bempedoic acid with ezetimibe (see also Nilemdo®) GREEN			RESTRICTED adults. Consultants in line with TA694
Nustendi ® tablets	PBRX NICE MMC BNF	emc _®	
Evinacumab			RESTRICTED a dults. Consultants in
RED		blueteq	line with TA1002
Repatha® injection	PBR X NICE MMC BNF	emc	
Evolocumab			RESTRICTED. Lipid Clinic
RED		blueteq	Consultants only for HoFH / & NICE
Repatha® injection	PBR X NICE MMC BNF	emc	TA394
Icosapent ethyl SA			RESTRICTED adults in line with NICE TA805
Vazkepa ® capsules	PBRX NICE MMC BNF	emc _®	
Inclisiran Green			RESTRICTED adults. Consultants in line with TA733
Leqvio ® injection	PBRX NICE MMC BNF	emc _®	for Primary Care Referral
Lomitapide			RESTRICTED adults. Lipid Clinic
RED EE		bluetea	Consultants in line with NHSE
Lojuxta® capsules	PbR X MMC BNF	emc	NI Engle
Volanesorsen			RESTRICTED adults. Lipid Clinic
RED EE		bluetea	Consultants in line with HST13
Waylivra® injection	PBR X NICE MMC BNF	emc	

2.13 Local sclerosants	Gw <mark>w</mark> wG	
Local Sclerosants		
Ethanolamine oleate RED injection	emc⊚	
Sodium tetradecyl sulfate RED injection	emc⊛	





Section 3: Respiratory system

Supported by the formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers Inhaler Devices

Nebuliser Diluent

3.2 Corticosteroids

Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants
- 3.6 Oxygen (refer to oxygen guidelines)
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
 - 3.9.1 Cough Suppressants

Cough Suppressants (Palliative Care ONLY)

- 3.9.2 Demulcent & expectorant cough preparations
- 3.10 Systemic Nasal Decongestants
- 3.11 Antifibrotics

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Idiopathic pulmonary fibrosis (CG163)

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

Asthma pathway (BTS, NICE, SIGN) (NG244)

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

Venom anaphylaxis - immunotherapy pharmalgen (TA246)

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)

Reslizumab for treating severe eosinophilic asthma (TA479)

Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)

Benralizumab for treating severe eosinophilic asthma (TA565)

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)

Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

Dupilumab for treating severe asthma with type 2 inflammation (TA751)

Palforzia for treating peanut allergy in children and young people (TA769)

Tezepelumab for treating severe asthma (TA880)

lvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)


GMMMG Formulary

Formulary Homepage


Chapter 3: Respiratory system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





3.1.4 Compound Bronchodilator Preparations		GMMG
Aclidinium bromide with formoterol fumarate dihydrate		3 rd line use
GREEN		COPD maintenance
Duaklir Genuair®	MMC BNF em	
Glycopyrronium bromide with formoterol fumarate		3 rd line use
GREEN		COPD maintenance
levespi Aerosphere®	MMC BNF emo	
Blycopyrronium bromide with indacaterol maleate		3 rd line use
GREEN		COPD maintenance
lltibro®	MMC BNF em	
pratropium bromide with salbutamol		
Combivent®	(BNF) (emc	
iotropium bromide monohydrate with olodaterol hydrochloride		3 rd line use
GREEN		COPD maintenance
Spiolto Respimat®	MMC BNF em	
Jmeclidinium bromide with vilanterol trifenatate		3 rd line use
GREEN		COPD maintenance
noro Ellipta®	MMC BNF emo	C
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GM <mark>X</mark> MG GM <mark>X</mark> MG GM <mark>X</mark> MG
nhaler Devices		
/olumatic® (spacer inhaler)		
GREEN	ENIT	
arge volume device with mouthpiece	NICE BNF em	
Aerochamber® Plus (spacer device)		
GREEN	(ES) NI (F	
standard device with mouthpiece; Standard device with adult face mask	NICE BNF	
Able Spacer® (spacer device)		
GREEN	ENIT	
	NICE MMC BNF	
lebuliser Diluent		
Sodium chloride		
GREEN	(B) NIF	
.9% nebuliser diluent	BNF	



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration








MMC

300mg; 600mg tablets




3.6 Oxygen (refer to oxygen guidelines)










3.8 Aromatic inhalations	Gw <mark>w</mark> wG
Aromatic Inhalations	
Benzoin Tincture, Compound, BP	
Friars' Balsam liquid	emc⊚
Menthol and Eucalyptus Inhalation, BP 1980	
	ENT
inhalation vapour	BNF emc



3.10 Systemic nasal decongestants Systemic Nasal Decongestants

GM<mark>M</mark>MG


NO DRUGS ARE RECOMMENDED FROM THIS GROUP



NHSE: OTC prescribing reduction

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)





Chapter 4: Central nervous system

Supported by the formulary (click here



- 4.1 Hypnotics & anxiolytics
 - 4.1.1 Hypnotics
 - 4.1.2 Anxiolytics
 - 4.1.3 Barbiturates
 - 4.1.4 Other hypnotics and anxiolytics
- 4.2 Drugs used in psychoses & related disorders
 - 4.2.1 Antipsychotic Drugs
 - 4.2.2 Antipsychotic Depot Injections
 - 4.2.3 Drugs used for mania and hypomania
- 4.3 Antidepressant drugs
 - 4.3.1 Tricyclic & Related Antidepressant Drugs
 - 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
 - 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
 - 4.3.4 Other Antidepressant Drugs
- 4.4 CNS stimulants & drugs used for ADHD
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea & vertigo
- 4.7 Analgesics
 - 4.7.1 Non-Opioid Analgesics
 - 4.7.2 Opioid Analgesics
 - 4.7.3 Neuropathic Pain
 - 4.7.4 Antimigraine Drugs
- 4.8 Antiepileptic drugs
 - Antiephephic drugs
 - 4.8.1 Control of the Epilepsies
 - 4.8.2 Drugs Used in Status Epilepticus
- 4.9 Drugs used in Parkinsonism & related disorders
 - 4.9.1 Dopaminergic Drugs Used in Parkinsonism
 - 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
 - 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
- Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Obsessive compulsive disorder (OCD) & body dismorphic disorder (BDD) (CG31)

Management of Obesity (CG43) (replaces TA22, TA31 & TA46)

Drug misuse: opioid detoxification (CG52)

Depression with a chronic physical health problem (CG91)

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

Anxiety (CG113) (replaces CG22)

Neuropathic pain - pharmacological management (CG173)

Psychosis and schizophrenia in adults (CG178)

Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Eating Disorders: recognition and treatment (NG69)

Parkinsons's disease in adults (NG71)

Attention deficit hyperactivity disorder: diagnosis and management (NG87)

Stop smoking interventions and services (NG92)

Dementia: supporting people with dementia and their carers in health and social care (NG97)

Post-traumatic stress disorder (NG116)

Depression in children and young people: identification and management (NG134)

Epilepsies in children, young people and adults (NG217)
Depression in adults: treatment and management (NG222)

Motor Neurone Disease: Riluzole (TA20)

Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)

Drug Misuse: Methadone & Buprenorphine (TA114)

Drug Misuse: Naltrexone (TA115) Smoking Cessation: Varenicline (TA123) Schizophrenia - aripiprazole (TA213)

Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Bipolar disorder (children) - aripiprazole (TA292)

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Vortioxetine for treating major depressive episodes (TA367)

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome (TA615)

Galcanezumab for preventing migraine (TA659)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

Fremanezumab for preventing migraine (replacing TA631) (TA764)

Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

Eptinezumab for preventing migraine (TA871)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Rimegepant for preventing migraine (TA906)

Rimegepant for treating migraine (TA919)

Daridorexant for treating long-term insomnia (TA922)

Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

Atogepant for preventing migraine (TA973)

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)


Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

GMMMG Formulary


Formulary Homepage

Chapter 4: Central nervous system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




4.1.3 Barbiturates NO DRUGS ARE RECOMMENDED FROM THIS GROUP 4.1.4 Other hypnotics and anxiolytics Daridorexant hydrochloride GREEN Quviviq ® tablets RESTRICTED in line with NICE TA922 NOT for initiation in 2^{ry} care




4.2.3 Drugs used for mania and hypomania		
Lithium carbonate		PRESCRIBE BY BRAND NAME
AMBER RED	ENTE for shildren	
tablets; M/R tablets	BNF emc	
Lithium citrate		PRESCRIBE BY BRAND NAME
AMBER RED	ENVE	
oral solution	BNF emco	
Valproic acid	BNP CITIES	
SI		
	for children	
Gastro-resistant tablets	BNF emc	
MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance		
MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended		


Section 4


Escitalopram		RESTRICTED Mental Health Trust initiation only
tablets	BNF emco	
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT	interval prolongation	
4.3.4 Other Antidepressant Drugs		
Venlafaxine GREEN SI		RESTRICTED
GREEN 31		initiation by Psychiatrist
M/R capsules; tablets; M/R tablets	MMC BNF emc	
Mirtazapine GREEN		
tablets; orodisperible tablets; oral solution	MMC BNF emc	
Duloxetine GREEN		RESTRICTED initiation by Psychiatrist
gastro-resistant tablets	BNF emco	
Flupentixol		RESTRICTED
		initiation by Psychiatrist
ablets	BNF emco	
Reboxetine		RESTRICTED
		initiation by Psychiatrist
ablets	MMC BNF emc	
Tryptophan		RESTRICTED
		initiation by Psychiatrist
capsules	BNF emco	
Vortioxetine		RESTRICTED
GREY SA		initiation by Psychiatrist
tablets	NICE MMC BNF CMC	



4.5 Drugs used in the treatment of obesity 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract Orlistat GREEN Consultant initiation - Paeds. only MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines







injection; rectal solution

Sulthiame U

Ospolot® 50mg tablets

Phenytoin sodium

capsules; oral suspension; injection

RESTRICTED

Consultant Neurologist use only


emc⊛


emc_®

BNF emc

MMC

MFT Formulary v10.7 (July 2025)	Section 4		Central Nervous System
4.9 Drugs used in Parkinsonism	& related disorders		Gм <mark>₩</mark> мG
.9.1 Dopaminergic Drugs Used in Parkinsonism			NICE NG71
mantadine hydrochloride			RESTRICTED
SA			Specialist use only
apsules; oral solution	NICE BNF	emc _®	
pomorphine hydrochloride	BNI	CITICO	RESTRICTED
AMBER			Specialist use only
	AND BARAO		opeoiding doc only
jection; infusion HRA Drug Safety Update (Apr-16): Apomorphine with domperidone: m	NICE MMC BNF	emc	
abergoline	III III III III III II II II II II II I		RESTRICTED
SA			Specialist use only
blets	NICE MANAGE CONTRACTOR	omo@	openance accomy
o-beneldopa	NICE MMC BNF	CITICO	RESTRICTED
SA			Specialist use only
			Specialist use only
apsules; M/R capsules; dispersible tablets	NICE BNF	emc⊕	DESTRICTES
SA		.	RESTRICTED Specialist use only
	E)NU tor, children		Specialist use Only
blets; M/R tablets (DNP) intestinal gel	PbR X NICE BNF	emc _®	DE0731073
Entacapone SA			RESTRICTED Specialist use only
			opecialist use only
ablets	NICE MMC BNF	emc⊚	
oslevodopa with foscarbidopa			RESTRICTED
	_		Specialist use only
roduodopa ® 240mg/mL / 12mg/mL infusion	NICE MMC BNF	emc⊚	
Opicapone GREY SA			RESTRICTED 2 nd line
GRET			Specialist use only
apsules	MMC BNF	emc⊚	
Pramipexole SA			RESTRICTED 3 rd line add-on use
SA			Specialist use only
ablets; M/R tablets	MMC BNF	emc⊚	
Rasagiline			RESTRICTED patients with end of
SA			dose fluctuations
ablets	MMC BNF	emc _®	
Ropinirole			RESTRICTED
SA			Specialist use only
blets; M/R tablets	BNF	emc⊚	
Rotigotine			RESTRICTED
SA			Specialist use only. NBM patients
ansdermal patches	NICE MMC BNF	emc	
Safinamide			RESTRICTED
SA			Specialist use only
ablets	MMC BNF	emc⊚	
Selegiline			RESTRICTED
SA			Specialist use only
ablets	RNE	emc _®	
.9.2 Antimuscarinic Drugs Used in Parkinsonism			
Orphenadrine hydrochloride			
SI	EUNE		
ral solution	RNE	emc⊚	
Procyclidine (Oral & IM)	BNF		
GREEN	N THE STATE OF THE		
ablets; oral solution; injection	ESINII for children	Omc@	
Trihexyphenidyl hydrochloride	BNF	emc⊚	
Thioxypholinayi nyaroomoliae			
	ENI		
ablet; syrup	MMC BNF	emc _®	





4.11 Drugs for dementia		Gм <mark>₩</mark> мG
4.11 Drugs for Dementia		NICE NG97
Donepezil hydrochloride SA		RESTRICTED Specialist use only
tablets; orodispersible tablets	NICE MMC BNF EMC®	
Galantamine SA		RESTRICTED Specialist use only
M/R capsules	NICE BNF emc	
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine hydrochloride		RESTRICTED Specialist use only
tablets; oral solution	NICE MMC BNF emc	
Rivastigmine GREEN		RESTRICTED Specialist use only
capsules; oral solution; transdermal patches	NICE MMC BNF emco	

		•
Non-Formulary Items		GM <mark>M</mark> MG
Aspirin and codeine		
(DNP)		in line with GMMMG
Co-codaprin® tablets; dispersible tablets	BNF emco	Criterion 2
Cannabis-derived, cannabis-based and hemp products (DNP)		in line with GMMMG
with the exception of nabilone and <i>Epidyolex</i> ®		Criterion 1
Dextropropoxyphene with paracetamol		in line with GMMMG
(DNP)		in line with GMMMG
Co-proxamol® Dosulepin hydrochloride	NICE BNF emc	
(DNP)		in line with GMMMG
tablets; capsules	BNF emco	Criterion 1
Electromagnetic pulse therapy		in line with GMMMG
(DNP)		
ActiPatch® Eplontersen sodium		Criterion 1 MFT not a commissioned centre
RED		patients referred to NAC - Royal Free
Wainzua ® 45mg/0.8mL injection	MMC BNF emc	
Eptinezumab red fr		
 _		NOT STOCKED
injection Erenumab	MMC BNF emc	HOI STOCKED
RED (£2)		
injection	NICE MMC BNF emc	NOT STOCKED
Ergotamine-containing products (ONP)		in line with GMMMG
e.g. Migril®		Criterion 1
Esketamine		
(DNP)		in line with GMMMG
Spravato ® nasal spray	NICE MMC BNF emc	Criterion 1
Fremanezumab (E)		
injection	NICE MMC BNF @CO	NOT STOCKED
Galantamine		RESTRICTED
	_	Specialist use only
4mg; 8mg & 12mg tablets Galcanezumab	NICE BNF EMC	
RED ff		
injection	MMC BNF emc	NOT STOCKED
Ganaxolone		in line with NICE
74-land Son Joseph and Automorphism	8888	
Ztalmy ® 50mg/mL oral suspension Haloperidol	NICE MMC emc	
(DNP)	ENIT	in line with GMMMG
500microgram tablets	NICE MMC BNF emc	Criterion 2
Infrequent migraine (ONP)		in line with GMMMG / NHSE
Levomepromazine		
(DNP)	BNF	in line with GMMMG
6mg tablets	BNF emco	
Loxapine (DNP)		in line with GMMMG
inhalation powder	BNF	Criterion 1
Meprobamate	JIII .	in line with GMMMG
(DNP)		
tablets Meprobamate		Criterion 1
(DNP)		in line with GMMMG
tablets		Criterion 1
Mild toothache / teething		in line with GMMMG / NHSE
(DNP)		IIIIIO WAI OMMING / MIGE
e.g. paracetamol, ibuprofen, teething gels.		

Minor conditions associated with pain, discomfort and/or (DNP)	in line with	GMMMG / NHSE
e.g. aches and sprains, headache, period pain, back pain		
Nicotine	in line v	vith GMMMG
(DNP)		VICII GININING
e-Voke®, Voke® (Nicotine inhaler)	Cri	terion 1
Omaveloxolone	Not recomi	mended by NICE
Skyclarys® 50mg hard capsules	NICE MMC emc	
Oxycodone with naloxone	in line v	vith GMMMG
(DNP)	III IIIIG V	
Targinact® M/R tablets	MMC BNF emc	terion 2
Paracetamol and tramadol	in line v	vith GMMMG
(DNP)	BNF	
ablets; effervescent tablets	BNF emc	terion 2
Paracetamol mixture / mucilage	in line v	vith GMMMG
(DNP)		
500mg / 5mL for topical use in patients with sore mouth or throat resulting from	ancer treatment Cri	terion 1
Paracetamol with buclizine and codeine (DNP)	in line v	vith GMMMG
	0	Andre d
Migraleve ® (all presentations) Paracetamol with isometheptene	<u> </u>	terion 1
(DNP)	in line v	vith GMMMG
Midrid® 325mg / 65mg caspules	Cri	terion 1
Sufentanil citrate	In the c	
(DNP)	In line v	vith GMMMG
Zalviso® 30microgram sublingual tablets	BNF emc	terion 2
Tafamidis	MFT not a con	nmissioned centre
RED TO THE PROPERTY OF THE PRO	patients referre	d to NAC - Royal Free
/yndaqel® capsules	NICE MMC BNF emc	
[ravel sickness (DNP)]	in line with	GMMMG / NHSE
/utrisiran	MET not a cou	nmissioned centre
RED		d to NAC - Royal Free
Amvuttra ® injection	NICE MMC BNF emc	

Section 5: Infections

Supported by the formulary (click here)



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antitleprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

5.6 Miscellaneous

Non-Formulary Items

Trust Guidelines

MFT Adult Antimicrobial guidelines

MFT Paediatric Antimicrobial guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Bacterial meningitis and meningococcal septicaemia (CG102)

Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)

Hepatitis B (Chronic) (CG165)

Tuberculosis (NG33)

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91)

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

Cough (acute): antimicrobial prescribing (NG120)

Surgical site infections: prevention and treatment (NG125)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Hepatitis B: Entecavir (TA153) Hepatitis B: Telbivudine (TA154)

Oseltamivir, Amantadine & Zanámivir for prophylaxis of Influenza (TA158) Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)

Hepatitis B: Tenofovir disoproxil (TA173)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Sofosbuvir for treating chronic hepatitis C (TA330)

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Ledipasvir-sofosbuvir for treating chronic hepatitis C (TA363)

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)

Sofosbuvir-velpatasvir for treating chronic hepatitis C (TA430)

Glecaprevir-pibrentasvir for treating chronic hepatitis C (TA499)

Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C (TA507)

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Cabotegravir with rilpivirine for treating HIV-1 (TA757)

Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

Bulevirtide for treating chronic hepatitis D (TA896)

Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

Molnupiravir for treating COVID-19 (TA1056)

GMMMG Formulary

Formulary Homepage

Chapter 5: Infections

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

RESTRICTED USE ANTIBIOTICS

- 1. Must be recommended / approved for use by consultant medical microbiologist
- 2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
- 3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

Cefotaxime

injection

Ceftriaxone

injection

injection

Cefuroxime

- 1. Can be used only in accordance with the restrictions outlined below.
- 2. Indication must be clearly documented on the prescription chart.

2. Indication must be clearly documented on the prescription char	t.	
3. If being used outside of guidelines Microbiology approval must b	e sought as above.	
UNRESTRICTED USE ANTIBIOTICS		
1. Can be used according to MFT Trust guidelines, (those drugs no	t marked Restricted or Reserv	/ed)
5.1 Antibacterial drugs		GM <mark>M</mark> MG
5.1.1 Penicillins		
5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin		
Benzylpenicillin sodium (Penicillin G)		
	FIME	
600mg injection	BNF emco	
Phenoxymethylpenicillin (Penicillin V)		
	[8]利[5]	
tablets	BNF emco	
Benzathine benzylpenicillin	BASHI	RESTRICTED
	BINIF	unlicensed treatment for syphilis
injection	BNF emc	
5.1.1.2 Penicillinase-Resistant Penicillins		
Flucloxacillin		
	TEN N.F.	
capsules; injection; oral solution	MMC BNF emc	
Temocillin		RESTRICTED infection caused by
		multi-resistant coliforms.
1g injection	MMC BNF emc	Micro only
5.1.1.3 Broad Spectrum Penicillins		
Amoxicillin		
	ES A TUP four challeform	
capsules; oral suspension; injection Co-amoxiclay	BNF emco	
Co-amoxiciav		
A-bloks	ESINIF for obliding	
tablets; oral suspension; injection 5.1.1.4 Antipseudomonal Penicillins	BNF emco	
Piperacillin with tazobactam		RESERVED
i ipordonini with tazosaotani		serious / resistant infections
injection	MMC BNF emco	
Ticarcillin with clavulanic acid	MIMO BNF CITCS	RESERVED
		serious / resistant infections
Timentin® 3.2g injection	MMC BNF emco	
5.1.1.5 Mecillinams	1011010	
Pivmecillinam hydrochloride		RESTRICTED UTIs caused by
- -		resistant coliforms
200mg tablets	MMC BNF emco	
5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams		BINIF BINIF STORES
		BNF BNF BNF
5.1.2.1 Cephalosporins		
Cefalexin		
	ESIMIF for children	
caspules; tablets; oral suspension	BNF emc	
Cefazolin		RESTRICTED
	BINIF to children	on Minne, achden ach
injection	MMC BNF emc	on Micro. advice only

BNF emc

BNF emc


BNF emc®


RESERVED as per guidelines for children

RESERVED as per guidelines for children

RESERVED as per guidelines for children

MFT Formulary v10.7 (July 2025)	Section 5	Infections
Cefixime		RESERVED
	(ESTATE)	GU infections only
tablets	MMC BNF emc	
Ceftazidime		RESERVED
	ISONIF for distribution	pseudomonas infection in CF
njection	MMC BNF emc	
Cetazidime with avibactam		RESERVED for
		gram negative organisms
Zavicefta® infusion Ceftolozane sulfate with tazobactam sodium	MMC BNF emc	Micro. Consultant only RESERVED for
Gentolozane Sunate with tazobactam Soutum		gram negative organisms
Zerbaxa® infusion	MMC BNF emc	
Ceftaroline fosamil	MIMIC BIT GITTE	RESERVED
	123条第四	CAP & cSSTI treatment.
Zinforo® infusion	MMC BNF emc	Micro. Consultant only
Cefoxitin		RESERVED for treatment of
	ESPORT Recognition on	mycobacterium abscessus in CF.
injection	MMC BNF emc	
Cefiderocol		RESERVED for
		gram negative organisms
Fetcroja® infusion	MMC BNF emc	Micro. Consultant only
5.1.2.2 Carbapenems Ertapenem		PECTRIATER
L. apononi	(MASSINGER)	RESTRICTED Outpatient therapy only
infusion	MMC BNF emc	
Imipenem with cilastatin		RESTRICTED
	238	Non-Tuberculous Mycobacteria in CF
infusion	MMC BNF emc	•
Imipenem with cilastatin & relebactam	1011010	
££		RESTRICTED
Recarbrio ® infusion	MMC BNF emc	Micro. Consultant only
Meropenem		RESERVED
	El Ni P	as per guidelines
injection	MMC BNF emc	
Meropenem with vaboractam		RESTRICTED
Vaborem ® infusion	MMC BNF emc	Micro. Consultant only
5.1.2.3 Other Beta-Lactam antibiotics Aztreonam		DESTRUCTED
Aztreonam		RESTRICTED gram negative organisms
injection	ISSIN [F] for delification	
Aztreonam lysine	BNF	RESTRICTED 3 rd line CF patients with
RED EE	21X(1)	chronic pulmonary infection
Cayston® nebuliser solution	MMC BNF emc	
Aztreonam with avibactam sodium	INITIO ENIZ	
	13 Miles	
Emblaveo® infusion	MMC BNF emc	
5.1.3 Tetracyclines		
Doxycycline		
	ESIN II-	
capsules; tablets; dispersible tablets	MMC BNF emc	
Oxytetracycline		
	ESINUF decrapidos	
Tablets	BNF emc	
Demeclocycline hydrochloride		RESTRICTED
	SING for strategies	SIADH only
capsules (see also section 6.5.2) Lymecycline	MMC BNF emc	
Lymecycline	Environment of the Control of the Co	RESTRICTED Non-Formulary
408mg capsules (see also section 13.6.2)	RABAC SANCE	1
Minocycline	MMC BNF emc	mino approved for GF referral
	1920 N (194	
capsules; tablets	MMC BNF @mc@	
Tigecycline	WWW SNP GIIC	RESERVED
		as per guidelines
infusion	MMC BNF emc	
	WIND CHICA	=1





tablets; infusion (see also section 11.3.1) Moxifloxacin tablets; infusion Nalidixic acid **RESTRICTED** Urology use in children only

BNF emc

Ofloxacin **RESTRICTED GU** infections only tablets (see also section 11.3.1) BNF emc MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects


MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk


MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection


MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour


tablets


MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients













Relenza® inhalation powder NICE MMC BNF emc Zanamivir **RESTRICTED** RED Virology approval only Dectova® 10mg/mL infusion NICE MMC BNF emc® 5.3.5 Respiratory Syncytial Virus (RSV) MHRA Drug Safety Update (Jul-25): Abrysvo ▼ (Pfizer) and Arexvy ▼ (GSK): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults **Palivizumab RESTRICTED** Specialist use only blueteq Synagis ® 100mg/mL injection PbR X MMC BNF emc Ribavirin RESTRICTED RED ££ Specialist use only PBRX NICE MMC BNF EMC®

capsules; tablets



5.4.5 Leishmaniacides		
Meglumine antimoniate	RESTRICTED)
RED	treatment of Leishma	niacides
njection	MMC BNF emc	
Paromomycin U	RESTRICTED)
RED	treatment of Crypotos	poridiosis
ablets	MMC BNF emc	
Sodium stibogluconate	RESTRICTED)
RED	treatment of Leishma	niacides
njection	MMC BNF emc	
5.4.7 Drugs for toxoplasmosis		
Sulfadiazine 0	RESTRICTED)
RED	treatment of toxopla	smosis
ablets	BNF emco micro. recommenda	tion only
5.4.8 Drugs for pneumocystis pneumonia		
Atovaquone U	RESTRICTED)
RED	Specialist use of	nly
oral suspension	BNF emco	
Pentamidine isethionate O	RESTRICTED)
RED	Specialist use of	nly
njection	BNF emco	



5.6 Miscellaneous


5.6 Miscellaneous antimicrobial treatments

Calcium sulphate

RED

Specialist use Diabetic Foot Clinic only

Stimulan ® antibiotic carrier beads



Section 6: Endocrine system

Supported by the formulary (click here)



6.1 Drugs used in diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

6.1.2.1 Sulphonylureas

6.1.2.2 Biguanides

6.1.2.3 Other antidiabetic drugs

Alpha glucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

6.1.4 Treatment of hypoglycaemia

6.1.5 Treatment of diabetic nephropathy and neuropathy

6.1.6 Diagnostic and monitoring agents for diabetes mellitus

6.2 Thyroid & antithyroid drugs

6.2.1 Thyroid hormones

6.2.2 Antithyroid drugs

6.3 Corticosteroids

6.3.1 Replacement therapy

6.3.2 Glucocorticoid therapy

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens & HRT

6.4.1.2 Progestogens and progesterone receptor modulators

6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin & parathyroid hormone

6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

6.7.1 Bromocriptine & other dopaminergic drugs

6.7.2 Drugs affecting gonadotrophins

6.7.3 Metyrapone

6.7.4 Somatomedins

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Safer insulin prescribing (KTT20)

Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

Type 1 diabetes in adults: diagnosis and management (NG17)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

Diabetic foot problems: prevention and management (NG19)

Type 2 diabetes in adults: management (NG28)

Heavy menstrual bleeding: assessment and management (NG88)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Human growth hormone - adults (TA64)

Diabetes (type 1) - insulin pump therapy (TA151)

Osteoporosis - Primary Prevention (TA160)

Osteoporosis - Secondary Prevention (TA161)

Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)

Osteoporotic Fractures - denosumab (TA204)

Bone metastases from solid tumours - denosumab (TA265)

Type 2 diabetes - Dapagliflozin combination therapy (TA288)

Diabetes (type 2) - canagliflozin (TA315)

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Bisphosphonates for treating osteoporosis (TA464)

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Liraglutide for managing overweight and obesity (TA664)

Romosozumab for treating severe osteoporosis (TA791)

Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

Somatrogon for treating growth disturbance in people 3 years and over (TA863)

Tirzepatide for treating type 2 diabetes (TA924)

Empagliflozin for treating chronic kidney disease (TA942)

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

Abaloparatide for treating osteoporosis after menopause (TA991)

Burosumab for treating X-linked hypophosphataemia in adults (TA993)

Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

Tirzepatide for managing overweight and obesity (TA1026)

Relugolix-estradiol-norethisterone for treating symptoms of endometriosis (TA1057)

Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

Linzagolix for treating symptoms of endometriosis (TA1067)

Dapagliflozin for treating chronic kidney disease (updates & replaces TA775) (TA1075)


GMMMG Formulary


Formulary Homepage

Chapter 6: Endocrine system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





MHRA Drug Safety Update (Nov-23): Ozempic ▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

MMC BNF emc

NICE MMC BNF emc

NICE MMC BNF emc

Ozempic ® injection

Semaglutide

Rybelsus® tablets

Mounjaro ® injection

Tirzepatide

GREEN


GREEN

RESTRICTED


as per by $\operatorname{\mathsf{GMMMG}}$


RESTRICTED

as per NICE / GMMMG T2DM pathway see also Non-formulary section



MHRA Drug Safety Update (Oct-24): Insulin pumps & CGM equipment: guidance for users on reporting suspected adverse incidents & safety concerns to the MHRA's Yellow Card





		•
6.4 Sex hormones		GM <mark>M</mark> MG
4.1 Female sex hormones and their modulators		
.4.1.1 Oestrogens & HRT		
onjugated oestrogens with progestogen		
remique® (Conjugated oestrogens with medroxyprogesterone)		2 nd line use oral
GREEN		(continuous combined HRT)
plets	BNF emco	(,
stradiol with Progestogen	Sit Cincs	
ijuve® (Estradiol with progesterone)		
GREEN		
mg/100mg capsules	MMC BNF emc	
Elleste-Duet® (Estradiol with norethisterone)	MINO BRIDGE	1 st line use oral
GREEN		(sequential HRT)
ablets	BNF emc	(coquertual titt)
Evorel Conti® (Estradiol with norethisterone)	BNF GIICS	
GREEN (
atch	MMC BNF emco	
Evorel Sequi® (Estradiol with norethisterone)	WINC BNF CITICS	
GREEN (ESTIMATOR WITH HOTOGRISCOTORIO)		
atab	AAAA A	
etch iemoston® (Estradiol with dydrogesterone)	MMC BNF emc	ond
GREEN (Estraciói with dydrogesterone)		2 nd line use oral
		(sequential HRT)
ablets	BNF emco	
(liovance® (Estradiol with norethisterone)		1 st line use oral
		(continuous combined HRT)
ablets	MMC BNF emc	
stradiol only		
Elleste Solo®		1 st line use oral
GREEN		(oestrogen only HRT)
blets	BNF emc	
Estradot ®		RESTRICTED
GREEN		(Oestrogen only HRT)
		when oral contraindicated.
vatch Evorel®	BNF emco	
GREEN GREEN		RESTRICTED
		Paed. Endocrine Consultants
vatch	MMC BNF emc	
enzetto ® GREEN		
ransdermal spray	MMC BNF emc	
Destrogel® GREEN		
GREEN		
06% gel (pump-pack)	MMC BNF emc	
Progynova®		RESTRICTED 2 nd line
RED		Paed. Endocrine Consultants
mg tablets	MMC BNF emc	
Sandrena ®		
GREEN		
00microgram; 1mg gel sachets	MMC BNF emc	
Ethinylestradiol, raloxifene & tibolone		
thinylestradiol		RESTRICTED
		adults: amenorrhoea
microgram tablets	MMC BNF emco	paeds: pubertal induction (3 rd line
Raloxifene hydrochloride	WOOD CITICO	RESTRICTED
SA		Specialist Med. Consultant only
blets	NICE MMC BNF emco	NICE TA160 / TA161
ibolone	WIMO DIVIDO CITICO	3 rd line use oral
GREEN		(continuous combined HRT)
phlate		(continuous combined filt)
s 4.1.2 Progestogens and progestorene recentor modulators	BNF emc®	
.4.1.2 Progestogens and progesterone receptor modulators		
dydrogesterone		
ablets	emc⊚	
Medroxyprogesterone acetate		
CALLA	(BIMIS)	
Depo-Provera® 150mg/mL injection	BNF emc	


Esmya ® 5mg tablets


MMC BNF emc®


MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury

MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment

MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users








Evenity ® injection

NICE MMC BNF emc



MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia

MF1 Formulary V10.7 (July 2025)	Section 6	Endocrine System
Non-Formulary Items		GM <mark>M</mark> MG
Carbimazole (DNP)		in line with GMMMG
10mg; 15mg tablets	MMC BNF emc	
Chlorpropamide (DNP)		in line with GMMMG
ablets	BNF	Criterion 1
Fezolinetant		
/eoza® 45mg tablets	BNF emc®	
MHRA Drug Safety Update (Apr-25): Fezolinetant ▼ (Veoza): risk of liver injur	y; new recommendations to minimise risk	
Gliclazide (DNP)		in line with GMMMG
Modified-release tablets (e.g. Diamicron® MR)	BNF emco	Criterion 2
Hypurin® Bovine Isophane		Discontinued July 2017
sophane insulin	emc⊚	
Hypurin® Bovine Lente		Discontinued July 2017
Insulin zinc suspension	emc	
Hypurin® Bovine Neutral		Discontinued July 2017
nsulin bovine	NICE @MC®	
Liraglutide RED		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Saxenda® 6mg/mL pre-filled pen	NICE MMC BNF emc	
Lixisenatide		Discontinued June 2022 / December 2023
_yxumia® 10 microgram; 20microgram injection	MMC BNF emc⊚	
Metformin hydrochloride (DNP)		in line with GMMMG
g immediate-release tablets	BNF emc	Criterion 2
Nateglinide		Discontinued August 2020
ablets	MMC BNF emc	
Pen needles 8mm, 10mm, or 12mm in length (DNP)		in line with GMMMG
		Criterion 1
Pen needles costing in excess of £5 per 100 (DNP)		in line with GMMMG
		Criterion 3
Semaglutide RED		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA
Wegovy® injection	NICE MMC BNF emc	
Sotagliflozin		Withdrawn August 2022
Zynquista ® 200mg tablets	NICE MMC emc®	
Tirzepatide (DNP)		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Mauriara ® injection	NICE MARKO	
Mounjaro ® injection	NICE MMC BNF EMC®	

Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the formulary (click here)



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Drugs affecting the ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Long-acting reversible contraception (CG30)

Lower urinary tract symptoms (CG97)

Nocturnal enuresis - the management of bedwetting in children and young people (CG111)

Antenatal and postnatal mental health: clinical management and service guidance (CG192)

Heavy menstrual bleeding: assessment and management (NG88)

Urinary incontinence and pelvic organ prolapse in women: management (NG123)

Caesarean birth (NG192)

Antenatal care for uncomplicated pregnancies (NG201)

Inducing labour (NG207)

Intrapartum care for healthy women and babies (NG235)

Overactive bladder - mirabegron (TA290)

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Vibegron for treating symptoms of overactive bladder syndrome (TA999)


GMMMG Formulary

Formulary Homepage


Chapter 7: Obstetrics, gynaecology & urinary tract disorders


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma







7.4 Drugs for genito-urinary disorders	G∞MMG
.4.1 Drugs for urinary retention	NICE CG97
lpha blockers	NICE CG111
	NICE NG123
lfuzosin hydrochloride ^{GREEN}	
olets BNF (er	
amsulosin hydrochloride	
GREEN	1 st line
apsules, tablets MMC BNF er	nc⊚
4.2 Drugs for urinary, enuresis & incontinence	
Irinary incontinence	NICE NG123
Oxybutynin hydrochloride GREEN	1 st line in OAB
Syn In to obtain	
ral solution; patch; tablets	nc _®
Parifenacin hydrobromide GREEN	1 st line in OAB
blets NICE MMC BNF @r	nc _®
Olterodine tartrate	1 st line in OAB
GREEN BALL	i ille ill OAB
apsules, tablets NICE MMC BNF @r	nc⊚
olifenacin succinate	2 nd line in OAB
ESTATION TO THE PROPERTY OF TH	
ablets MMC BNF @r	nc®
Puloxetine GREY GREEN	
apsules MMC BNF @r	nc 🏽
rospium chloride	RESTRICTED
GREEN	1 ^{RY} Care referral only
apsules; tablets ### Airabegron	nc⊚ Restricted
GREEN	in line with TA290 / Paeds 3 rd line
ablets NICE MMC BNF ET	nc _®
IHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and	· · · · · · · · · · · · · · · · · · ·
libegron	RESTRICTED in line with TA999
Obgemsa ® 75 mg tablets	
locturnal enuresis	
mitriptyline hydrochloride	
GREEN	
ral solution; tablets (see also section 4.3.1)	nc 🏽
Desmopressin	RESTRICTED
SI	Haematology Consultants only
jection; nasal spray; tablets (see also section 6.5.2)	nc⊚
.4.3 Drugs used in urological pain	
Methionine ①	RESTRICTED
	resistant calcium phosphate lithiasis
	European Association of Urology
entosan polysulfate sodium	RESTRICTED Urology Cons. in line with NICE
apsules NICE MMC BNF (ET	
HRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy	
otassium citrate	
GREEN OTC	
ablets (DNP) mild cystitis (2-3 days)	nc _®
otassium citrate 0	
RED	
rocit ®-K extended release tablets MMC	nc (a)

7.4.4 Bladder instillations & urological surgery			
<u>Chlorh</u> exidine			
RED	BRF		
0.02% irrigation solution	BNF	emc _®	
Dimethyl sulfoxide (1)			
50% solution		emc⊛	
Glycine			
1.5% irrigation solution	BNF	emc⊕	
Sodium chloride			
RED	BINIF		
0.9% irrigation solution	BNF	emc⊕	
Sodium citrate			
RED	BRF		
3% irrigation solution	BNF	emc⊕	
Sodium hyaluronate			RESTRICTED
RED			Urology Consultants only
Cystistat® 40mg/50mL bladder instillation	MMC	emc⊕	
Sodium hyaluronate with sodium chondroitin sulfate			RESTRICTED
RED			Urology Consultants only
iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	MMC	emc⊛	
7.4.5 Drugs for erectile dysfunction			
Alprostadil			RESTRICTED
GREEN	(S)N(F) for children		Urology Consultants only
cream; injection; urethral sticks	MMC BNF	<u>emc</u>	
Aviptadil with phentolamine mesilate			RESTRICTED
SI			Urology Consultants only
Invicorp® injection	MMC BNF	<u>emc</u> ⊚	
Sildenafil			RESTRICTED
GREEN OF RED PAH	(B)N(F) for children		1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)	MMC BNF	emc⊕	
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero e	xposure in a clinica	Il trial on intra	
Tadalafil GREEN OF RED PAH			RESTRICTED
			1 ^{RY} Care referral only
tablets (see also section 2.5.1)	MMC BNF	emc⊚	DECTR: 0770
Vardenafil			RESTRICTED
			1 ^{RY} Care referral only
tablets	MMC BNF	emc	
7.4.6 Drugs for premature ejaculation (DNP)			
NOT STOCKED			

Non-Formulary Items		$G^{MM}MG$
Dapoxetine hydrochloride (DNP)		in line with GMMMG
Priligy ® 30mg; 60mg tablets	BNF emco	Criterion 1
Doxazosin (DNP)	BNIF	in line with GMMMG
mg M/R tablets; 8mg tablets	BNF emco	Criterion 2
Licensed and off-label topical anaesthetics (DNP)		in line with GMMMG
		Criterion 1
lild cystitis (2-3 days)		in line with GMMMG / NHSE
.g. Potassium citrate mixture or sachets, cranberry products		
Tadalafil (DNP)		in line with GMMMG
.5mg tablets	BNF emco	Criterion 2
CONP)		in line with GMMMG
100microgram / 500microgram hard capsules	BNF emco	Criterion 1

Section 8: Malignant disease & immunosuppression

Supported by the formulary (click here)



8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NICE Guidance

Advanced breast cancer (CG81)

Familial breast cancer (CG164)

Hepatitis B (chronic) (CG165)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)

Early and locally advanced breast cancer: diagnosis and management (NG101)

Lung cancer: diagnosis and management (NG122)

Prostate cancer: diagnosis and management (NG131)

Colorectal cancer (NG151)

Temozolomide for malignant glioma (TA23)

Leukaemia (lymphocytic) - fludarabine (TA29)

Trastuzumab for advanced breast cancer (TA34)

Paclitaxel for ovarian cancer (TA55)

Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)

Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)

Docetaxel for prostate cancer (hormone-refractory) (TA101)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Paclitaxel for early breast cancer (TA108)

Docetaxel for early breast cancer (TA109)

Gemcitabine for Breast Cancer (TA116)

Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)

Leukaemia (lymphocytic) - fludarabine (TA119)

Carmustine implants and temozolomide for gliomo (newly diagnosed & high grade) (TA121)

Pemetrexed for lung cancer (non small cell) (TA124)

Multiple sclerosis - natalizumab (TA127)

Bortezomib for relapsed multiple myeloma (TA129)

Pemetrexed for mesothelioma (TA135)

Rituximab for follicular non-Hodgkin's lymphoma (TA137)

Head and neck cancer - cetuximab (TA145)

Renal cell carcinoma - sunitinib (TA169)

Lenalidomide - multiple myeloma (TA171)

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

Renal Cell Carcinoma (TA178)

Sunitinib for gastrointestinal stromal tumours (TA179)

Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)

Cervical cancer (recurrent) - topotecan (TA183)

Lung cancer (small cell) - topotecan (TA184)

Soft tissue sarcoma - trabectedin (TA185)

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)

Gastric cancer (advanced) - capecitabine (TA191)

Lung cancer (non-small-cell, first line) - gefitinib (TA192)

Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)

Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)

Colorectal cancer (metastatic) - bevacizumab (TA212) Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)

Renal cell carcinoma (1st line metastatic) - pazopanib (TA215) Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Myelodysplastic syndrome - azacitidine (TA218)

Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)

Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)

Osteosarcoma - mifamurtide (TA235)

Follicular lymphoma - rituximab (review TA110) (TA243)

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)

Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)

Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Multiple sclerosis (relapsing) - teriflunomide (TA303)

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Multiple myeloma - bortezomib (induction therapy) (TA311)

Section 8 Malignant disease

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5g cytogenetic abnormality (TA322)

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Olaparib forovarian, fallopian tube and peritoneal cancer (TA381)

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Trifluridine-tipiracil for previously treated metastatic colorectal cancer (TA405)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

Talimogene laherparepyec for treating unresectable metastatic melanoma (TA410)

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)

Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)

Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)

Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Cladribine tablets for treating relapsing-remitting multiple sclerosis (TA493)

Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)

Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Tivozanib for treating advanced renal cell carcinoma (TA512)

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)

Cabozantinib for treating medullary thyroid cancer (TA516)

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)
Midostaurin for untreated acute myeloid leukaemia (TA523)
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Ocrelizumab for treating relapsing-remitting multiple sclerosis (TA533)

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Dinutuximab beta for treating neuroblastoma (TA538)

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

Cabozantinib for untreated advanced renal cell carcinoma (TA542)

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Padeliporfin for untreated localised prostate cancer (TA546)

Vandetanib for treating medullary thyroid cancer (TA550)

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia (TA552)

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)

Cladribine for treating relapsing-remitting multiple sclerosis (TA616)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis (TA624)

Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)

Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)

Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)

Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)

Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)

Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)

Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

Ofatumumab for treating relapsing multiple sclerosis (TA699)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)

Midostaurin for treating advanced systemic mastocytosis (TA728)

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)

Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

Ponesimod for treating relapsing-remitting multiple sclerosis (TA767)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)

Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer…. (TA786)

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

Diroximel fumarate for treating relapsing-remitting multiple sclerosis (TA794)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)

Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)

Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)

Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802) Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)

Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852) Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)

Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)

Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)

Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

Regorafenib for previously treated metastatic colorectal cancer (TA866)

Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia...(TA893)

. (TA895) Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)

Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)

Ruxolitinib for treating polycythaemia vera (TA921)

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

Targeted-release budesonide for treating primary IgA nephropathy (TA937)

Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)

Durvalumab with gemeitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)

oncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)

lvosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)

Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)

Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)

Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)

lvosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

Relugolix for treating hormone-sensitive prostate cancer (TA995)

Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)

Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

Trifluridine-tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

Avapritinib for treating advanced systemic mastocytosis (TA1012)

Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021)

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023) Ublituximab for treating relapsing multiple sclerosis (TA1025)

Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for resectable NSCLC (TA1030)

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy (TA1034)

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer (TA1036)

Pembrolizumab for adiuvant treatment of resected non-small-cell lung cancer (TA1037)

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug... (TA1038)

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug... (TA1039)

Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma (TA1048)

Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-cell ALL (TA1049)

Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

Ruxolitinib for treating acute GvHD that responds inadequately to corticosteroids in people 12 years and over (TA1054)

Rucaparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer... (TA1055)

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

Osimertinib for untreated EGFR mutation-positive advanced NSCLC (TA1060)

Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer (TA1063)

Dostarlimab for treating primary advanced or recurrent endometrial cancer with MSI-H or dMMR (TA1064)

Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with MSI-H or dMMR (TA1065)

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (updates & replaces TA823) (TA1071)

Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)

Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)


GMMMG Formulary


Formulary Homepage

Chapter 8: Malignant disease & immunosuppression

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





Asciminib RED ft Scemblix ® 20mg/40mg tablets	blueteq	RESTRICTED Haem. Consultants in line with NICE TA813
Asparaginase RED infusion	MMC BNF emc	RESTRICTED Haematology Consultants only
Axicabtagene ciloleucel RED ES Yescarta ® infusion	Diveted	RESTRICTED in line with NICE TA872
Bevacizumab RED FF Avastin® 100mg in 4mL vial	blueteq	RESTRICTED Haematology Consultants only
Bortezomib RED (£)	blue <mark>teq</mark>	RESTRICTED Haematology Consultants only
Brentuximab vedotin RED (1)	PBRX NICE MMC BNF @mc	RESTRICTED Haematology Consultants only
Adcetris infusion Brexucabtagene autoleucel RED (E)	PBRX NICE MMC BNF emc	RESTRICTED Haem. Consultants only in line with NICE / CDF
Tecartus ® infusion Cabozantinib RED ED CE CE CE CE CE CE CE CE CE	PBRX NICE MMC BNF @mc blueteq	RESTRICTED Specialist Consultant use only in line with NICE
tablets; capsules Carfilzomib RED ED	PBR X NICE MMC BNF EMC®	NOT STOCKED RESTRICTED Haematology Consultants only in line with NICE
infusion Ceritinib RED EE	PBRX NICE MMC BNF @MC®	RESTRICTED Respiratory Consultants only in line with NICE
Cetuximab RED (12)	PBRX NICE MMC BNF @MC®	NOT STOCKED RESTRICTED Haematology Consultants only in line with NICE
infusion Crisantaspase RED ED	PBR X NICE MMC BNF EMC®	RESTRICTED Haematology Consultants only
Dacarbazine RED	BNF emc	RESTRICTED Haematology Consultants only
Durvalumab RED (1)	BNF emc	RESTRICTED Respiratory Consultants only in line with NICE
infusion Entrectinib RED Entrection	PBRX NICE MMC BNF CMC Diveted PBRX NICE MMC BNF CMC CM	RESTRICTED Specialist Consultant use only in line with NICE
Eribulin RED (£) injection	Diveteq	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Erlotinib RED Ef	PBR X NICE MMC BNF @mc	RESTRICTED Respiratory Consultants only in line with NICE NOT STOCKED
Everolimus RED (£) tablets		RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Hydroxycarbamide AMBER capsules; tablets (see GMMMG below)	BNF emc	RESTRICTED Haematology Consultants only
Hydroxycarbamide RED Xromi® oral liquid	MMC BNF emc®	RESTRICTED Paediatric patients with swallowing difficulties
Ipilimumab RED (1) infusion	blueteq	RESTRICTED Dermatology Consultants only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytologidenib		RESTRICTED Haematology Consultants only in line with NICE
Tibsovo ® 250mg tablets	PBRX NICE MMC BNF EMCO	

RED EE		RESTRICTED Haematology
	blueteq	O - m - million to a million to the man million
capsules	PERX NICE MMC BNF emc	_
Lorlatinib	ionore Emberral	RESTRICTED Respiratory
RED EE		Consultants only in line with NICE
Lander a Stableto	blueteq	
Lisocalitagene maralousel	PBRX NICE MMC BNF emc	PECTRICIES II Committee II
Lisocabtagene maraleucel		RESTRICTED Haem. Consultants
	blueteq	only in line with NICE / CDF
Breyanzi® infusion	PBRX NICE MMC BNF EMC®	
Midostaurin RED FF		RESTRICTED Haematology
RED EE	blueteq	Consultants only in line with NICE
Rydapt® capsules	PBRX NICE MMC BNF emc	
Nintedanib esilate		RESTRICTED Respiratory
RED EE	blueteq	Consultants only in line with NICE
Ofev® capsules	PBRX NICE MMC BNF EMC	
Nintedanib esilate		RESTRICTED Respiratory
RED ££	blueteq	Consultants only in line with NICE
Vargatef® capsules	PBRX NICE MMC BNF emc	NOT STOCKED
Niraparib	CITICS	RESTRICTED Gynaecology
RED ££	[alored A a a	Consultants only in line with NICE
	blueteq	NOT STOCKED
Zejula ® capsules MHRA Drug Safety Update (Oct-20): Niraparib (Zejula ▼): reports of severe hypertension	PBRX NICE MMC BNF emc	HOTOTOCKED
Panitumumab	a raco, particularly in early freatment	PESTRICTED Hoomsteleau
RED (£)		RESTRICTED Haematology Consultants only in line with NICE
	blueteq	•
infusion Parabin actat	PBRX NICE MMC BNF emc	NOT STOCKED
Panobinostat RED RED		RESTRICTED Haematology
NED 12		Consultants only in line with TA380
capsules	PBR X NICE MMC BNF EMC®	
Pegaspargase		RESTRICTED
RED EE	RIVIE	Haematology Consultants only
Oncaspar® injection	PBR X NICE MMC BNF emc	
Pembrolizumab		RESTRICTED Specialist use only in
RED EE	BNI blueteq	line with NICE / NHSE
infusion	PBRX NICE MMC BNF emco	
MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼):		
Pentostatin		RESTRICTED
RED ££		
		Haematology Consultants only
infusion	BNF emco	Haematology Consultants only
infusion Pertuzumab	BNF emc	
		RESTRICTED Specialist Consultant
Pertuzumab (EE)	blueteq	RESTRICTED Specialist Consultant use only in line with NICE
Pertuzumab RED (ff) infusion		RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Pertuzumab RED III infusion Procarbazine	blueteq	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED
Pertuzumab RED (ff) infusion Procarbazine RED (ff)	PERX NICE MMC BNF EMC®	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Pertuzumab RED (12) infusion Procarbazine RED (12) capsules	blueteq	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only
Pertuzumab RED (E) infusion Procarbazine RED (E) capsules Sacituzumab govitecan	PERX NICE MMC BNF EMC®	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant
Pertuzumab RED III infusion Procarbazine RED III capsules Sacituzumab govitecan RED III	PERX NICE MMC BNF EMC®	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy® infusion	PBRX NICE MMC BNF @mc@	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant
Pertuzumab RED II infusion Procarbazine RED III capsules Sacituzumab govitecan RED III Trodelvy® infusion Selinexor	PBRX NICE MMC BNF emc@	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy® infusion	BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED
Pertuzumab RED II infusion Procarbazine RED III capsules Sacituzumab govitecan RED III Trodelvy® infusion Selinexor	PBRX NICE MMC BNF emc@	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant
Pertuzumab RED	BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE
Pertuzumab RED	BNF emco BNF emco BNF emco BNF emco BNF emco BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy® infusion Selinexor RED ff Nexpovio® tablets Sorafenib RED ff	BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy® infusion Selinexor RED ff Nexpovio® tablets Sorafenib RED ff tablets	PARX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy® infusion Selinexor RED ff Nexpovio® tablets Sorafenib RED ff	PARX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology
Pertuzumab RED (12) infusion Procarbazine RED (12) capsules Sacituzumab govitecan RED (12) Trodelvy ® infusion Selinexor RED (12) Nexpovio ® tablets Sorafenib RED (12) tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors:	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE
Pertuzumab RED fff infusion Procarbazine RED fff capsules Sacituzumab govitecan RED fff Trodelvy ® infusion Selinexor RED fff Nexpovio ® tablets Sorafenib RED fff tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: Sotorasib RED fff	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only
Pertuzumab RED	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781
Pertuzumab RED ff infusion Procarbazine RED ff capsules Sacituzumab govitecan RED ff Trodelvy infusion Selinexor RED ff Nexpovio tablets Sorafenib RED ff tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: Sotorasib RED ff	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology
Pertuzumab RED	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410
Pertuzumab RED	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410
Pertuzumab RED	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria
Pertuzumab RED	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria
Pertuzumab RED	PARX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria
Pertuzumab RED (12) infusion Procarbazine RED (12) capsules Sacituzumab govitecan RED (12) Trodelvy ® infusion Selinexor RED (12) Nexpovio ® tablets Sorafenib RED (12) tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: Sotorasib RED (12) Lumykras ® tablets Talimogene laherparepvec RED (12) injection Tisagenlecleucel RED (12) Kymriah ® infusion Trastuzumab	BNF emco BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria
Pertuzumab RED (12) infusion Procarbazine RED (12) capsules Sacituzumab govitecan RED (12) Trodelvy ® infusion Selinexor RED (12) Nexpovio ® tablets Sorafenib RED (12) tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: Sotorasib RED (12) Lumykras ® tablets Talimogene laherparepvec RED (12) injection Tisagenlecleucel RED (12) Kymriah ® infusion	BNF emco BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria and NICE TA975 RESTRICTED Specialist use only in
Pertuzumab RED (12) infusion Procarbazine RED (12) capsules Sacituzumab govitecan RED (12) Trodelvy ® infusion Selinexor RED (12) Nexpovio ® tablets Sorafenib RED (12) tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: Sotorasib RED (12) Lumykras ® tablets Talimogene laherparepvec RED (12) injection Tisagenlecleucel RED (12) Kymriah ® infusion Trastuzumab	PBRX NICE MMC BNF emco	RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Haematology Consultants only RESTRICTED Specialist Consultant use only in line with NICE NOT STOCKED RESTRICTED Specialist Consultant use only in line with NICE RESTRICTED Haematology Consultants only in line NICE / NHSE RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781 RESTRICTED Dermatology Consultants only in line with TA410 RESTRICTED in line with CDF criteria and NICE TA975 RESTRICTED Specialist use only in

Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications

Other agents

Hydroxycarbamide - Sickle Cell Disease

Isotretinoin RED

RESTRICTED Specialist use only for the management of neuroblastoma

capsules; liquid (20mg/mL unlicensed preparation) (see also section 13.6.2) MMC BNF emc Platinum compounds

Cisplatin

iniection BNF emc® RESTRICTED

Haematology Consultants only

Protein kinase inhibitors

Abemaciclib RED ££ blueteq Verzenios® tablets PBR X NICE MMC BNF emc

RESTRICTED Specialist use only in line with NICE **NOT STOCKED**

MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases

Alectinib RED ££ blueteq Alecensa® capsules PER X NICE MMC BNF emco

RESTRICTED Specialist use only in line with NICE TA536 / TA1014

Alpelisib RED ££

blueteq

RESTRICTED Specialist use only in line with NICE TA816

Piqray ® tablets Avapritinib

PBR X NICE MMC BNF emc

NOT STOCKED RESTRICTED Specialist use only in

Ayvakyt® tablets

blueteq PBRX NICE MMC BNF emc line with NICE TA1012

Axitinib Inlyta® tablets blueteq

PBRX NICE MMC BNF emc

RESTRICTED Haematology Consultants only in line with NICE **NOT STOCKED**

Bosutinib RED EE

Bosulif® tablets

PBRX NICE MMC BNF emc

RESTRICTED Haematology Consultants only in line with TA401

MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation

Brigatinib RED ££ Alunbrig® tablets PBRX NICE MMC BNF emc

RESTRICTED Specialist use only in line with NICE

Crizotinib RED ££

PBR X NICE MMC BNF EMC

bluetea

blueteq

blueteq

RESTRICTED Specialist use only in line with NICE

Xalkori® capsules **Dabrafenib** RED ££ Tafinlar® capsules

PBRX NICE MMC BNF emc

blueteq

Specialist use only in line with NICE RESTRICTED

RESTRICTED

Dabrafenib RED ££

blueteq PBRX NICE MMC BNF emc

Specialist use only in line with NICE

Dacomitinib RED EE Vizimpro ® tablets

PBR X NICE MMC BNF emc

RESTRICTED Specialist use only in line with NICE **NOT STOCKED**

Dasatinib RED ££

Finlee® dispersible tablets

blueteq

RESTRICTED Haematology Consultants only

Sprycel® tablets; powder for oral suspension PBRX NICE MMC BNF emco MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation

Encorafenib RED ££ Braftovi® capsules

blueteq PBRX NICE MMC BNF emco

RESTRICTED Specialist use only in line with NICE **NOT STOCKED**

Fedratinib RED

blueteq

RESTRICTED **Haematology Consultants only**

Inrebic® capsules Gefitinib RED ££

PBRX NICE MMC BNF emc

tablets

Mylotarg® injection

PBRX NICE MMC BNF emc

RESTRICTED Specialist use only in line with NICE **NOT STOCKED**

Gemtuzumab ozogamicin RED EE





RESTRICTED Haematology Consultants only

PBRX NICE MMC BNF emco Zynlonta® infusion Mobocertinib **RESTRICTED** Specialist use only RED EE bluetea Exkivity® capsules PBRX NICE MMC BNF emc Momelotinib **RESTRICTED** Specialist use only in RED ££ line with NICE TA957 blueteq Omjjara® tablets PBRX NICE MMC BNF emc Neratinib

Haematology Consultants only blueteq Tasigna® capsules PBRX NICE MMC BNF emc MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation **Osimertinib RESTRICTED** Specialist use only in RED (££) line with NICE blueteq Tagrisso® tablets PBRX NICE MMC BNF emco **Palbociclib RESTRICTED** Specialist use only in line with NICE blueteq

NOT STOCKED Ibrance ® capsules PBRX NICE MMC BNF emc

MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases **Ponatinib RESTRICTED** Specialist use only in

line with NICE TA451 Iclusia® tablets PBRX NICE MMC BNF EMC®

MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome

MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation

MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events

RED E

Nilotinib

Nerlyny® tablets

Quizartinib dihydrochloride RED £ blueteq Vanflyta® tablets

PBRX NICE MMC BNF emc Regorafenib

blueteq

Stivarga® 40mg tablets PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

RESTRICTED Specialist use only in line with NICE TA1013

RESTRICTED Specialist use only in

line with NICE TA612

NOT STOCKED


RESTRICTED

blueteq

PBRX NICE MMC BNF emc

RESTRICTED Specialist use only in line with NICE TA488 / TA555 **NOT STOCKED**

capsules BNF emc Taxanes **Paclitaxel** RESTRICTED **Haematology Consultants only** Infusion PBRX NICE MMC BNF emc MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error Cabazitaxel **RESTRICTED** RED EE **Haematology Consultants only** blueteq Jevtana® Infusion PBRX NICE MMC BNF emc



Interferon beta-1b

BCG bladder instillationBacillus Calmette-Guérin

OncoTICE® bladder instillation

Bacillus Calmette-Guérin

BCG-medac® intravesical suspension

RED £

iniection

RESTRICTED Specialist use only in

line with NICE TA527

NOT STOCKED

RESTRICTEDSpecialist use only

RESTRICTED
Specialist use only

blueteq

BNF emc

MMC BNF emc

PBRX NICE MMC BNF CMC



Teriflunomide tablets

PBRX NICE MMC BNF emc

blueteq

RESTRICTED Specialist use only in line with NICE TA303

> **NOT STOCKED RESTRICTED** Haematology

Consultants only


Thalidomide

capsules


PBRX NICE MMC BNF emc

MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years


MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies



NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)







Section 9: Nutrition & blood

Supported by the formulary (click here)



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.1.8 Haemophilia

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance
- 9.3 Intravenous nutrition

9.4 Oral nutrition

9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Nutrition support in adults (CG32)

Coeliac disease: recognition, assessment and management (NG20)

Chronic kidney disease: assessment and management (NG203)

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Migalastat for treating Fabry disease (HST4)

Eliglustat for treating type 1 Gaucher disease (HST5)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)

Lumasiran for treating primary hyperoxaluria type 1 (HST25)

Hyperparathyroidsim - cinacalcet (TA117)

Thrombocytopenic purpura - romiplostim (TA221)

Thrombocytopenic purpura - eltrombopag (TA293)

Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)

Etelcalcetide for treating secondary hyperparathyroidism (TA448)

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Patiromer for treating hyperkalaemia (TA623)

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

Avalglucosidase alfa for treating Pompe disease (TA821)

Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)


GMMMG Formulary


Formulary Homepage


Chapter 9: Nutrition & Blood


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List









Bicarbonate and lactate		
Sodium bicarbonate		
	ISMI	
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	BNF emco	
Sodium lactate compound		
	国外協	
(Hartmann's solution) infusion	BNF emc	
Water		
Water for Injections		
injection	emc⊚	
9.2.2.2 Plasma & plasma substitutes		
Dextran		
Dextran 40 - 10% in sodium chloride 0.9% infusion	emc ⊚	
Dextrose Acid Citrate ACDA		
solution	emc ⊚	
Gelatin		
Gelofusine® infusion	RNE PMC	

9.3 Intravenous nutrition

BNF







Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)

NICE CG32

9.4 Oral nutrition			GM <mark>M</mark> MG
Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)			NICE CG32
9.4.1 Nutrition in special diets Sapropterin dihydrochloride			DECTRICTED
RED (2)	IS N	blueteq	RESTRICTED Tetrahydrobiopterin deficiency
Kuvan® 100mg soluble tablets	MMC BN	emc	England
LaBiNIC® probiotic drops			RESTRICTED
			prevention of NEC
LaBiNIC® probiotic drops	MMC	<u>emc</u>	



Calcium acetate with magnesium carbonate		RESTRICTED
SI		Renal Consultants only
Osvaren® 435mg/235mg tablets	MMC BNF emc	
anthanum		RESTRICTED
SI RED		Renal Consultants only
hewable tablets; oral powder (RED dialysis; SI non-dialysis)	MMC BNF emc	
atiromer calcium		RESTRICTED Consultants only
AMBER		in line with NICE TA623
∕eltassa® oral powder	NICE MMC BNF @mc	
Sevelamer carbonate		RESTRICTED
SI	RINIF	Renal Consultants only
Renvela® 800mg tablets; 2.4g; 0.8g sachets	PARX NICE MMC BNF emcs	
Sucroferric oxyhydroxide		RESTRICTED
RED EE		Renal Consultants only - 3 rd line
hewable tablets	MMC BNF emc	
0.5.3 Fluoride		
Sodium fluoride		
	BNE	
ablets, paediatric drops, dental rinse	BNF emc	
.5.4 Zinc		
linc sulfate		
	[83N]F	
Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules	BNF emco	




9.6.6 Vitamin K	
Phytomenadione	
GREEN	以以后
Konakion® MM & Konakion® MM Paediatric injection	MMC BNF emc
Menadiol sodium phosphate	
GREEN	ES N TO
oral solution; tablets	MMC BNF emc
9.6.7 Multivitamin preparations	
Vitamins B,C	RESTRICTED
Renavit® tablets	MMC BNF emco
Vitamins A,D,E,K	RESTRICTED
GREY SI	Paediatric CF patients
Paravit-CF® capsules; liquid	MMC BNF emc

9.7 Bitters & tonics




Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use




PbR X

MMC BNF emc

capsules; oral suspension





Section 10: Musculoskeletal & joint diseases

Supported by the formulary (click here)



10.1 Drugs used in rheumatic diseases & gout

10.1.1 Non-steroidal anti-inflammatory drugs

10.1.2 Corticosteroids

10.1.3 Drugs that suppress the rheumatic disease process

Gold

Penicillamine

Antimalarials

Drugs affecting the immune response

Cytokine modulators

10.1.4 Gout and cytotoxic induced hyperuricaemia

10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

10.2.1 Drugs that enhance neuromuscular transmission

10.2.2 Skeletal muscle relaxants

Nocturnal leg cramps

10.2.3 Drugs used in neuromuscular disorders

10.3 Drugs for the relief of soft-tissue inflammation

10.3.1 Enzymes

10.3.2 Rubefacients & other topical antirheumatics

10.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Rheumatoid arthritis in adults: management (NG100)

Osteoarthritis in over 16s: diagnosis and management (NG226)

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)

Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)

Hyperuricaemia - febuxostat (TA164)

Psoriasis - ustekinumab (TA180)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)

Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)

Psoriatic arthritis - golimumab (TA220)

Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)

Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)

Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Apremilast for treating active psoriatic arthritis (TA433)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)

Tocilizumab for treating giant cell arteritis (TA518)

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Nusinersen for treating spinal muscular atrophy (TA588)

Upadacitinib for treating severe rheumatoid arthritis (TA665)

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

Anakinra for treating Still's disease (TA685)

Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)

Ixekizumab for treating axial spondyloarthritis in adults (TA718)

Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)

Tofacitinib for treating juvenile idiopathic arthritis (TA735)

Upadacitinib for treating moderate rheumatoid arthritis (TA744)

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)

Risdiplam for treating spinal muscular atrophy (TA755)

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)

Upadacitinib for treating active ankylosing spondylitis (TA829)

Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

Bimekizumab for treating axial spondyloarthritis (TA918)

Tofacitinib for treating active ankylosing spondylitis (TA920)

Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

GMMMG Formulary

Formulary Homepage

Chapter 10: Musculoskeletal & Joint Diseases


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


100mg; 200mg tablets

10.1 Drugs used in rheumatic diseases & gout GM<mark>M</mark>MG 10.1 Drugs used in rheumatic diseases & gout **NICE CG177** BNF BNF 10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs) NICE NG100 MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks Ibuprofen (oral) 1st line use 200mg; 400mg; 600mg tablets; 5% gel MMC BNF emc® MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk Ibuprofen (IV) short-term symptomatic treatment of acute moderate pain 200mg in 50ml solution for infusion MMC BNF emc MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk Naproxen BNF emc 250mg; 500mg tablets MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy Celecoxib **RESTRICTED** - osteoarthritis in line with NICE NG226 100mg; 200mg capsules MMC BNF emc MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks Diclofenac sodium **RESTRICTED** - acute post-operative pain (injection) 50mg tablets; suppositories; injection (restricted post-op pain) MMC BNF emc MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings Flurbiprofen 50mg tablets Indometacin **RESTRICTED** 3rd line (off-label) for tocolysis capsules; suppositories MMC BNF emc Mefenamic acid 250mg; 500mg tablets BNF emce Meloxicam 7.5mg; 15mg tablets emc_® Sulindac 100mg; 200mg tablets MMC BNF emc **Etodolac RESTRICTED** Consultant Anaesthetist use only 600mg tablets MMC BNF emc® Phenylbutazone **RESTRICTED** Specialist use only, ankylosing spondylitis

BNF emc



MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose




Rheumatology Consultants only NICE MMC BNF emc tablets MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric ▼): stop treatment if signs or symptoms of serious hypersensitivity

Hyperuricaemia associated with cytotoxic drugs

GREEN


Rasburicase **RESTRICTED** RED EE **Haematology Consultants only** blueteq Fasturtec® infusion PbR X MMC BNF emc

10.1.5 Other drugs for rheumatic diseases NICE CG177 **NICE TA477 NICE TA508**



PBRX NICE MMC BNF emc

oral solution



10.4 Miscellaneous preparations				GM <mark>M</mark> MG	
Dibotermin alfa (1) RED (12)				RESTRICTED NHSE CCP 16063/P	NHS England
InductOs®	PbR X	MMC	<u>emc</u> ⊛		England
Givinostat				RESTRICTED	
RED EE		(B))	JI(F)	DMD patients aged 6 years & o	lder
Duvyzat® 8.86mg/mL oral suspension	PbR X	MMC (B)	IF emc⊚		
Glucarpidase				RESTRICTED	
RED EE			NE -	2 nd line rescue therapy	
Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 13.14)	PbR X	MMC (B)	emc		NHS England

Non-Formulary Items		Gм <mark>¥</mark> мG
Efgartigimod alfa	blueteq	MFT not a commissioned centre Patients referred to NCA
Vyvgart® injection; infusion	PBRX NICE MMC BNF EMCO	
Glucosamine		in line with GMMMG
with or without chondroitin	BNF	
Hyaluronan injections (DNP)		in line with GMMMG
injection including hyaluronan and sodium hyaluronate	BNF	
Naproxen with esomeprazole (DNP)		in line with NICE / GMMMG
	BNF emco	
Satralizumab (DNP)		in line with NICE / GMMMG
Enspryng® injection	NICE BNF CMC	
Sodium aurothiomalate		Discontinued June 2019
injection	BNF emco	

Section 11: Eye

Supported by the formulary (click here)



11.3 Anti-infective eye preparations

- 11.3.1 Antibacterials
- 11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

- 11.4.1 Corticosteroids
- 11.4.2 Other anti-inflammatory preparations

11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

Beta-blockers

Prostaglandin analogues and prostamides

Combination products (prostaglandin analogue with beta-blocker)

Combination products (prostaglandin analogue with Rho kinase inhibitor)

Sympathomimetics

Carbonic anhydrase inhibitors

Miotics

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

- 11.8.1 Tear deficiency, ocular lubricants & astringents
- 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment
- 11.8.3 Other preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Glaucoma: diagnosis and management (NG81)

Age-related macular degeneration (NG82)

Diabetic retinopathy: management and monitoring (NG242)

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Macular degeneration (age related) ranibizimab & pegaptanib (TA155)

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)

Macular oedema (diabetic) - ranibizumab (TA274)

Macular oedema (retinal vein occlusion) - ranibizumab (TA283)

Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)

Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)

Aflibercept for treating diabetic macular oedema (TA346)

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Aflibercept for treating choroidal neovascularisation (TA486)

Cenegermin for treating neurotrophic keratitis (TA532)

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uvetitis (TA590)

Brolucizumab for treating wet age-related macular degeneration (TA672)

Faricimab for treating diabetic macular oedema (TA799)

Faricimab for treating wet age-related macular degeneration (TA800)

Brolucizumab for treating diabetic macular oedema (TA820)

Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

Tebentafusp for treating advanced uveal melanoma (TA1027)

GMMMG Formulary

Formulary Homepage

Chapter 11: Eye


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


11.3 Anti-infective eye preparations	GM <mark>M</mark> MG
11.3.1 Antibacterials	
Chloramphenicol	
GREEN OTC (DNP)	
0.5% eye drops, 1% eye ointment ((DNP) bacterial conjunctivitis)	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2	years
Fusidic acid (ophthalmic) GREEN	
ENG.	
1% eye drops BNF emc®	
Amikacin (ophthalmic)	RESTRICTED microbial keratitis.
	Consultant Ophthalmologist only
2.5% eye drops Amphotericin 0	NOT STOCKED
RED	RESTRICTED Consultant Ophthalmologist only
0.45% and described	Ophthalmologist only
0.15% eye drops Azithromycin (ophthalmic)	RESTRICTED Consultant
RED RED	Ophthalmologist only
Azyter ® 1.5% eye drops MMC BNF @mc.	op.i.a.iiiiioog.ee e.i.;
Ceftazidime (ophthalmic)	RESTRICTED Consultant
RED	Ophthalmologist only
5% eye drops BNF emc	NOT STOCKED
Cefuroxime (ophthalmic)	RESTRICTED Consultant
RED	Ophthalmologist only
5% eye drops BNF emc	
Cefuroxime (intracameral injection)	RESTRICTED Consultant
RED	Ophthalmologist only
Ximaract ® 50mg in 5mL intracameral injection MMC BNF @mc ®	
Chlorhexidine (ophthalmic)	RESTRICTED acanthamoeba
SINC.	keratitis. Consultant only
0.02% eye drops BNF emc	
Ciprofloxacin (ophthalmic)	RESTRICTED microbial keratitis.
GAM P	Consultant Ophthalmologist only
0.3% eye drops MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour	
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irrever	sible side effects
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other thera	peutic options first in patients at risk
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-la	
Erythromycin (ophthalmic)	RESTRICTED superficial eye
GiA F	infections
0.5% eye ointment Gentamicin (ophthalmic)	DESTRUCTED Consultons
RED	RESTRICTED Consultant Ophthalmologist only
1.5% and draps (Hea with entureying and draps)	opinal annoing for only
1.5% eye drops (Use with cefuroxime eye drops) Levofloxacin (ophthalmic)	RESTRICTED Consultant only
RED	corneal ulcers/ keratitis
0.5% eye drops MMC BNF emc®	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour	
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irrever	
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other thera	•
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-la Natamycin	RESTRICTED fungal keratitis,
	conjunctivitis, fungal blepharitis
5% eye drops	, , ,
Ofloxacin	RESTRICTED Consultant
RED INVESTIGATION OF THE PROPERTY OF THE PROPE	Ophthalmologist only
0.3% eye drops MMC BNF @mC®	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour	
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irrever	
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other theral MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lateral properties of the description of the properties of the description of the descript	
Penicillin (ophthalmic)	RESTRICTED microbial keratitis.
RED	Consultant Ophthalmologist only
2,500 units/mL eye drops	
Polyhexamethylene biguanide (PHMB)	
RED	
0.02% eve drops	NOT STOCKED

Propamidine isetionate ①	RESTRICTED Consultant
	Ophthalmologist only
0.1% eye drops	BNF emc
Vancomycin (ophthalmic)	RESTRICTED gram positives,
RED	including MRSA but not VRE
	C=20 V.O. for edition
5% eye drops	BNF emc NOT STOCKED
11.3.3 Antivirals	
Ganciclovir	
SI	
	LE) NUCL for children
0.15% eye gel	BNF emc
Trifluorothymidine U	
RED	THE REAL PROPERTY AND ADDRESS OF THE PERTY ADDRES
	SOLINO TO CONTRACT OF THE PROPERTY OF THE PROP
1% eye drops	BNF EMC®


Eye







11.7 Local anaesthetics	GMMG
Ocular Local anaesthetics	
Fluorescein with lidocaine (minims)	
RED	BRIT
4% / 0.25% eye drops	BNF emc
Oxybuprocaine hydrochloride (minims)	
RED	BINIF or enlature
0.4% eye drops	BNF emc®
Proxymetacaine hydrochloride (minims)	
RED	ENIT
0.5% eye drops	BNF emc
Tetracaine (Amethocaine) (minims)	
RED 1% & 2% eye drops	ans ame



Fluorescells sodium 115	8.2 Ocular diagnostic & peri-operative preparations &	рногопунанно пеаштет		
## A Commencial fries up a drops Fluorescella fries up a drops Processed	ular diagnostic preparations			
RESTRICTED Consultation of the properties of the		_		
RESTRICTED Consultation of the production of the	0.004	for	SNIF	
Specialist use on fundation fundation with proton fundation fundat	· · · · · · · · · · · · · · · · · · ·	E	NF emc⊕	DESTRICTED
Completed preserved in preserved in the preserved in th		_		
RESTRICTED Consultant periodic florid from the product periodic florid from the periodic florid			SN[5 ohlidren	
Specialist use on Survive of Entropy of Engine Activity of Engine Acti		MMC	NF emc	
Apraclonidine Sergivit. spection Ocular peri-operative drugs Apraclonidine Sergivit. Sergivit. spection Ophthalimologist o Opht				
Coulse peri-operative drugs Activicholine chloride RESTRICTED Consu Ophthalmologist o Ophthalmologist				
Accepticholine chloride Substance Comment		MMC	<u>emc</u> ⊕	
Ophthalmologist o Ophthalmologi				
The part of the pa	etylcholine chloride	_		
Apracionidine Section Comment		i≅ fer	SN[5 ohlidren	Ophthalmologist only
Ophthalmologist o Ophthalmolog	<u> </u>	B	NF emc	
Securification of the second s		_		
RESTRICTED Consultant pseudophakic CM Cettorlact trometamol (25) (Septiment of the property of the pseudophakic CM Cettorlact trometamol (25) (Septiment of		for	N (5 children	Ophthalmologist only
Pediatric 0.3 mg/mt. eye drops Ketorolac trometamol RESTRICTED Consu Ophthalmologist o MMC BNI GMC RESTRICTED Intraocular to of inferior retinal br of inferior retinal br of inferior retinal br of inferior retinal br devance 8 th mg/mt. eye drops MMC RESTRICTED Intraocular to of inferior retinal br devance 8 th mg/mt. eye drops MMC RESTRICTED Consu Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist o Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthal		В	NF emc	
RESTRICTED Consusure of the providence of the pr	omienac			
RESTRICTED Consus Ophthalmologist o RESTRICTED				· · ·
Cophthalmologist o Cophe we drops RESTRICTED. 1st in popular on the cophe of the c		MMC CE	emc®	
Acutar © 1.5% eye drops Nepafenac RESTRICTED. 1 ²⁴ line pos surgery in diabetics. 2 nd Nevanac © 1 mg/mL eye drops Povidone-locdine RESTRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist o Ophthalmologist o RESTRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist o Ophthalmologist o RESTRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist o Ophthalmologist o RESTRICTED Consus Ophthalmologist on RESTRICTED Consus Op				
RESTRICTED. 1st line poes surgery in diabetics. 2nd Surgery in diabeti		Es for	SINF	
Surgery in diabetics. 2 nd Povidone-lodine Povidone-lodine RESTRICTED Consu Ophthalmologist o MMC BNF SmC RESTRICTED intraocular t of inferior retinal br			NF emc	
Povidone-lodine Povidone - Coline RESTRICTED Consus Ophthalmologist o Ophthalmolo	ратепас			
RESTRICTED Consus Ophthalmologist o WMC BINE BETRICTED intraocular to of inferior retinal brown RESTRICTED Consus Ophthalmologist o WMC BINE BETRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist on RESTRICTED Consus				
Ophthalmologist of inferior retinal brown of inferior of inferior retinal brown of inferior retinal brown of inferior of inferior retinal brown of inferior of inferior retinal brown of inferior of i	• • •	MMC (E	emc®	
RESTRICTED intraccular to finferior retinal brown of inferior retinal brown ophthalmologist of inferior problems of inferior retinal brown of inferior retinal brown ophthalmologist in line very long in 4mL line to inferior brown of inferior brown ophthalmologist in line very long in 4mL line to inferior brown ophthalmologist in line very long in 4mL line long in 4mL	vidone-iodine			RESTRICTED Consultant
Heavy Silicone oil Persion © 68 - 10mL syringe MMC Subfoveal choroidal neovascularisation Alfibercept ### Common Co		Ke	NNF children	
Subfoveal choroidal neovascularisation Affilibercept Subfoveal choroidal neovascularisation RESTRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist in line w Afficiants RESTRICTED Consus Ophthalmologist o RESTRICTED Consus Ophthalmologist in line w RESTRICTED Consus Ophthalmologist in line w RESTRICTED Consus Ophthalmologist in line w Ophthalmologist in line w RESTRICTED Consus Ophthalmologist in line w		MMC (E	emc®	
Dension © 68 - 10mL syringe Subfoveal choroidal neovascularisation Allibercept Allibercept Allibercept Sevacion (a) (a) (b) (b) (c) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	avy Silicone oil			RESTRICTED intraocular tamponad
Affilibercept AFED (1) EVER				of inferior retinal breaks
ARIIbercept RESTRICTED Consu Ophthalmologist o Sevice® 40mg in mL injection Resvacizumab ① Resvacizumab ② Ophthalmologist o Restricted Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist in line v RESTRICTED Consu Ophthalmologist in line v RESTRICTED Consu Ophthalmologist in line v RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist in line v	, ,	MMC		
Several young in time. Injection Eyea 9 40mg in time. Injection Bevacizumab				
Eyea © 40mg in 1mL injection Bevacizumab				RESTRICTED Consultant
RESTRICTED Consus Ophthalmologist or Avastin® 10mg in 4mL vial PRES MMC BNF EMC Ophthalmologist or Ophthalmo				Ophthalmologist only
Avastin® 100mg in 4mL vial Bovacizumab gamma RED 10		PBR X NICE MMC B	NF emc®	
Avastin® 100mg in 4mL vial Bevacizumab gamma RESTRICTED Consu Ophthalmologist o Lytenava® 25 mg/mL injection RED (a) RED (b) RED (c) RED (c) RESTRICTED Consu Ophthalmologist o Lytenava® 25 mg/mL injection RED (c) RED (c) RED (c) RED (c) RESTRICTED Consu Ophthalmologist o Ophthalmologist o RESTRICTED Consu Ophthalmologist o RED (c) RESTRICTED Consu Ophthalmologist in line w RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o RED (c) RED (c) RED (c) RED (c) RESTRICTED Consu Ophthalmologist o RED (c) RED (c) RED (c) RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist o RESTRICTED Consu Ophthalmologist in line w RED (c) RESTRICTED Consu Ophthalmologist in line w				RESTRICTED Consultant
RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RED (a) RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RED (a) RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RED (a) RED (a) RESTRICTED Consuctiveness 25 mg/mL injection RESTRICTED Consuctiveness 25			blueteq	Ophthalmologist only
Ophthalmologist of Characteristic Consustance of Characteristic Characteristic Characteristic Characteristic Characteristic C		PBR X MMC E	NF emc	
### A District Consusion				RESTRICTED Consultant
RED (2) Ophthalmologist or Opht				Ophthalmologist only
Ophthalmologist o Beovu® 120mg in 1mL injection MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu♥): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals RESTRICTED Consumption RED 11 RED 12 RED 13 RESTRICTED Consumption RED 13 RESTRICTED Consumption RED 14 RESTRICTED Consumption RED 15 RESTRICTED Consumption Virteomacular traction 11.8.3 Other preparations Voretigene Voretige		PBR X NICE MMC B	NF emc®	
Beovu® 100mg in 1mL injection MMRA Drug Safety Update (Jan-22): Brolucizumab (Beovu ▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals RESTRICTED Consumply				RESTRICTED Consultant
MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu ♥): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals RESTRICTED Consus Ophthalmologist in line was the policy of the properties of the policy of	(ED)			Ophthalmologist only
RESTRICTED Consumption	ovu® 120mg in 1mL injection	PBR X NICE MMC B	NF emc	
Ophthalmologist in line w Vabysmo® 120mg/mL injection Ranibizumab RED ## Cophthalmologist on line w RESTRICTED Consus Ophthalmologist on Ophthalmologist on Ophthalmologist on Ophthalmologist on RESTRICTED Consus Ophthalmologist on Ophthalmologist on Ophthalmologist on RESTRICTED Consus Ophthalmologist on RESTRICTED Consus Ophthalmologist on RESTRICTED Consus Ophthalmologist in line w Ophthalmologist on RESTRICTED Consus Ophthalmologist in line w		lar inflammation and retinal vascular oc	clusion increase	
Valoysmo® 120mg/mL injection Ranibizumab RED				RESTRICTED Consultant
Ranibizumab RED (12) Cucentis ® I Ongavia ® 10mg/mL injection Verteporfin RED (12) Visudyne ® 15mg vial Vitreomacular traction Vitreomacular traction Voretigene Voretigene Voretigene neparvovec RED (12) Cucumuma 2 mL vial Cucumuma 2 mL				Ophthalmologist in line with NICE
Ophthalmologist of Ophthalmologi		PBR X NICE MMC B	NF emc	TA799 / TA800 / TA1004
Verteporfin RED II Visudyne ® 15mg vial Vitreomacular traction 11.8.3 Other preparations Voretigene Voretigene neparvovec RED II Voretigene neparvovec RED II RESTRICTED Consumption of the consumption of				RESTRICTED Consultant
Verteporfin RED ED Visudyne © 15mg vial Vitreomacular traction 11.8.3 Other preparations Voretigene Voretigene Voretigene neparvovec RED ED Luxturna® 2mL vial Insulin eye drops Insulin (soluble) eye drops RESTRICTED Consu Ophthalmologist in line w RESTRICTED RESTRICTED				Ophthalmologist only
Ophthalmologist o Visudyne © 15mg vial Vitreomacular traction 11.8.3 Other preparations Voretigene Voretigene Voretigene neparvovec RED (12) RESTRICTED Consumption Diueted Diueted Dissulin eye drops Insulin (soluble) eye drops RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED		PBR X NICE MMC E	NF emc	Engl.
Visudyne © 15mg vial Vitreomacular traction 11.8.3 Other preparations Voretigene Voretigene neparvovec RESTRICTED Consu Ophthalmologist in line w Luxturna® 2mL vial Insulin eye drops Insulin (soluble) eye drops RESTRICTED RESTRICTED RESTRICTED RESTRICTED				RESTRICTED Consultant
Vitreomacular traction 11.8.3 Other preparations Voretigene Voretigene neparvovec RED (1) Luxturna® 2mL vial Insulin (soluble) eye drops RESTRICTED Consu Ophthalmologist in line vitre (soluble) eye drops RESTRICTED RESTRICTED				Ophthalmologist only
## A Comparison of the Compari		PbR X MMC (E	emc	d
Voretigene Voretigene neparvovec RED ED DIE DIUE TEQ LUXTURIA PORX NICE MMC EMCO RESTRICTED Consu Ophthalmologist in line w LUXTURIA PORX NICE MMC RESTRICTED RESTRICTED RESTRICTED	reomacular traction			
Voretigene Voretigene neparvovec RED ED DIVERSITY OF THE PORT OF T				
Voretigene neparvovec RED ED DIUE TEQ Diue T				
Cophthalmologist in line we will blue teq with the control of the				
Luxturna® 2mL vial Insulin eye drops RESTRICTED				RESTRICTED Consultant
Luxturna® 2mL vial Insulin eye drops Insulin (soluble) eye drops RESTRICTED	(ED III)		blueteq	Ophthalmologist in line with NICE
Insulin (soluble) eye drops U		PBR X NICE MMC		
DED				
Consultant Onlythalms				
Consultant Ophthaline				Consultant Ophthalmologist
Humulin S® in Systane® lubricant eye drops MMC	nulin S® in Systane® lubricant eye drops	MMC		

Non-Formulary Items		GMMMG
Cenegermin		DISCONTINUED January 2020
Oxervate®	NICE	
Commercial eyelid cleansing preparations (DNP)		in line with GMMMG
		Criterion 1
Conjunctivitis (bacterial) (DNP)		in line with GMMMG / NHSE
Chloramphenicol eye drops or ointment.		
Conjunctivitis (viral) (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops Ory eyes / sore tired eyes		
(DNP)		in line with GMMMG / NHSE
Hypromellose eye drops, carbomer 980 gel, hyaluronate eye drops		
Ocriplasmin RED (f)		DISCONTINUED May 2020
etrea® 0.5mg/0.2mL injection	PBRX NICE MMC BNF emc	
Polymyxin B sulfate		DISCONTINUED November 2017
Poly (carboxymethylglucose sulfate)	BNF emco	BIGGONERNIES
roly (carboxymethylglucose sulfate)		DISCONTINUED December 2019
Nacial@ ava dura - (0.00ml)	84840	December 2019
Cacicol® eye drops (0.33mL) Simple eye ointment	MMC BNF emc	
(DNP)		in line with GMMMG
	BNF emco	Criterion 1
Tebentafusp		NOT STOCKED. Patients treated at commissioned centre in Liverpool
Kimmtrak ® 200micrograms/mL infusion	PBRX NICE MMC BNF emc	

Section 12: Ear, nose & oropharynx

Supported by the formulary (click here



- 12.1 Drugs acting on the ear
 - 12.1.1 Otitis externa
 - 12.1.3 Removal of ear wax
- 12.2 Drugs acting on the nose
 - 12.2.1 Drugs used in nasal allergy
 - 12.2.2 Topical nasal decongestants
 - 12.2.3 Nasal preparations for infection
- 12.3 Drugs acting on the oropharynx
 - 12.3.1 Drugs for oral ulceration & inflammation
 - 12.3.2 Oropharyngeal anti-infective drugs
 - 12.3.4 Mouthwashes, gargles & dentifrices
 - 12.3.5 Treatment of dry mouth

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
Non-formulary Conversion Table

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)
Sore throat (acute): antimicrobial prescribing (NG84)
Otitis media (acute): antimicrobial prescribing (NG91)
Tinnitus: assessment and management (NG155)
Otitis media with effusion in under 12s (NG233)


Allergic rhinitis (CKS)


GMMMG Formulary


Formulary Homepage

Chapter 12: Ear, nose & oropharynx

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List







Non-Formulary Items	GM <mark>M</mark> MG
Acute sore throat (DNP)	in line with GMMMG
Sore throat lozenges and sprays, analgesics	
Coughs, colds and nasal congestion (DNP)	in line with GMMMG
Pseudoephedrine nasal sprays and oral preparations. Xylometazoline and ephedrine nasal sprays and drops	
Ear wax removal (DNP)	in line with GMMMG
Olive oil, sodium bicarbonate ear drops. Includes prior to syringing	
Mouth ulcers (DNP)	in line with GMMMG
Local anaesthetic gels, hydrocotrisone buccal tablets	
Oral thrush (DNP)	in line with GMMMG
Miconazole oral gel, nystatin oral suspension	

Section 13: Skin

Supported by the formulary (click here)



13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

13.3 Topical local anaesthetics & antipruritics

13.4 Topical corticosteroids

13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response Cytokine Modulators

13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

13.7 Preparations for warts & calluses

13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

13.9 Shampoos & other preparations for scalp/hair conditions

13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasiticidal preparations

13.10.5 Preparations for minor cuts & abrasions

13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 lodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

13.12 Antiperspirants

13.13 Topical circulatory preparations

13.14 Miscellaneous preparations

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Atopic eczema in children (CG57)

Psoriasis: assessment and management (CG153)

Pressure Ulcers (CG179)

Pubic lice CKS (2011)

Scabies CKS (2011)

Acne vulgaris CKS (2014)

Head lice CKS (2015)

Surgical site infections: prevention and treatment (NG125)

Atopic dermatitis (eczema) - topical steroids (TA81)

Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)

Psoriasis - efalizumab and etanercept (TA103)

Psoriasis - infliximab (TA134)

Psoriasis - adalimumab (TA146)

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Psoriasis - ustekinumab (TA180)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)

Apremilast for treating active psoriatic arthritis (TA433)

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Dimethyl fumarate for treating moderate to severe plague psoriasis (TA475)

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Guselkumab for treating moderate to severe plague psoriasis (TA521)

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Certolizumab pegol for treating moderate to severe plague psoriasis (TA574)

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Baricitinib for treating moderate to severe atopic dermatitis (TA681)

Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

Bimekizumab for treating active psoriatic arthritis (TA916)

Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

Nivolumab-relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

Spesolimab for treating generalised pustular psoriasis flares (TA1070)

Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

GMMMG Formulary


Formulary Homepage


Chapter 13: Skin

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

EMA (efalizumab)






13.4 Topical corticosteroids GMMMGCorticosteroid only preparations **NICE TA81** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration **HYDROCORTISONE Potency** Canesten HC® Mild GREEN hydrocortisone 1% plus clotrimazole 1% cream BNF emc Daktacort® Mild hydrocortisone 1%, miconazole nitrate 2% cream; ointment BNF emc Eurax-hydrocortisone® Mild hydrocortisone 0.25%, crotamiton 10% cream BNF emc® Fucidin H® Mild GREEN hydrocortisone 1%, fusidic acid 1% cream BNF emc Terra-Cortril® Mild hydrocortisone 1%, oxytetracycline 3% ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate Moderate GREEN betamethasone valerate 0.025% ointment, cream BNF emc Betnovate-RD® Moderate GREEN betamethasone valerate 0.025% cream: ointment BNF emc **CLOBETASONE BUTYRATE Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions **Eumovate**® **Moderate** GREEN Clobetasone butvrate 0.05% cream: ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate **Potent** GREEN betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion BNF emc Betnovate® **Potent** GREEN Betamethasone valerate 0.1% cream; ointment; scalp application; lotion BNF emc Betamethasone valerate with clioquinol **Potent** BNF emc betamethasone valerate 0.1% / clioquinol 3% ointment; cream Betamethasone valerate with neomycin sulfate Potent betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment BNF emc® Diprosalic ® Potent Betamethasone dipropionate 0.05%, salicylic acid 3% ointment BNF emc Fucibet® **Potent** GREEN betamethasone valerate 0.1% plus fusidic acid 2% cream BNF emc Betnovate® Potent

betamethasone valerate ointment 25% in coal tar

DERMATOLOGY ONLY


CLOBETASOL PROPIONATE		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, remin	der of possible severe side effects, including w	ithdrawal reactions
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of top	oical steroid withdrawal reactions	
Dermovate ®		
GREEN		Very potent
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	BNF	
Dermovate NN®		
		Very potent
clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	BNF emc	
Etrivex®	BNF CITICS	
GREEN		Very potent
clobetasol propionate 500micrograms/g shampoo	MMC BNF emc	RESTRICTED - 1 ^{ry} Care referral
DIFLUCORTOLONE VALERATE		Potency
Diflucortolone valerate 0		
		Very potent
diflucortolone valerate 0.3% oily cream	MMC emc	RESTRICTED Consultant Gynaecologist

13.5 Preparations for eczema & psoriasis GMMMG 13.5.1 Preparations for eczema Alitretinoin RESTRICTED **Dermatology Consultants only** 10mg; 30mg capsules PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women 13.5.2 Preparations for psoriasis Topical preparations for psoriasis NICE CG153 Calcipotriol RESTRICTED GREEN **Dermatology Consultants only** Dovonex® ointment: with Betamethasone (Dovobet® 0.05% ointment) BNF emc® **Dithranol RESTRICTED Dermatology Consultants only** Dithocream® 0.1% & 0.25% cream BNF emc Salicylic acid **RESTRICTED Dermatology Consultants only** Zinc & Salicylic acid paste BP (Lassar's Paste) BNF emc **Tacalcitol** RESTRICTED **Dermatology Consultants only** Curatoderm® lotion: ointment BNF emc Tars Coal tar paste BP RESTRICTED **Dermatology Consultants only** BNF emc Coal tar with salicylic acid and precipitated sulfur RESTRICTED **Dermatology Consultants only** Cocois® scalp ointment BNF emc Oral retinoids for psoriasis Acitretin **RESTRICTED** RED **Dermatology Consultants only** 10mg; 25mg capsules BNF emc Dimethyl fumarate **Dimethyl fumarate** RESTRICTED RED ££ 3rd/4th line as per NICE/GMMMG blueteq **Referral to SRFT** 30mg; 120mg tablets PBR X NICE MMC BNF emc 13.5.3 Drugs affecting the immune response **Abrocitinib RESTRICTED Dermatology Consultants only** blueteq in line with NICE Cibingo ® 50mg; 100mg; 200mg tablets PBRX NICE MMC BNF @MC® MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality **Azathioprine RESTRICTED Dermatology Consultants only** 25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3) PbR X NICE BNF emc® MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy Ciclosporin **RESTRICTED Dermatology Consultants only PRESCRIBE BY BRAND** 25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2) PbR X MMC BNF emc® Methotrexate RESTRICTED **Dermatology Consultants only** 2.5mg tablets (see also sections 8.1.3 & 10.1.3) MMC BNF emc **Pimecrolimus RESTRICTED Dermatology Consultants only** % cream NICE MMC BNF emc **Sirolimus RESTRICTED Dermatology Consultants only** Hyftor® 0.2% gel (see also section 8.2.2) MMC BNF emc Tacrolimus (specially made by SRFT) RESTRICTED **Dermatology Consultants only** 0.03%; 0.1% ointment (see also section 8.2.2) PBRX NICE MMC BNF CMC Upadacitinib **RESTRICTED** RED EE **Dermatology Consultants only** blueteq in line with NICE Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3) PBRX NICE MMC BNF emc MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality





PBRX NICE MMC BNF emc


Wezenla® injection (see also sections 1.5.3 & 10.1.3)



MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders








13.10 Anti-infective skin preparations GM<mark>M</mark>MG 13.10.1 Antibacterial preparations Topical antibacterials should generally be avoided for the treatment of infections 13.10.1.1 Antibacterial preparations only used topically Mupirocin 2% cream; ointment MMC BNF emc Fusidic acid **RESTRICTED** superficial impetigo 2% cream: ointment BNF emc Metronidazole RESTRICTED GREEN topical treatment of rosacea 0.75% topical gel; cream BNF emc® Silver sulfadiazine **RESTRICTED** GREEN Treatment/prophylaxis of burns 1% w/w cream BNF emc 13.10.2 Antifungal preparations **Amorolfine** 1st line antifungal for nail infections 5% nail lacquer MMC BNF emc® Benzoic acid with salicylic acid 1st line treatment of ringworm benzoic acid 6% / salicylic acid 3% / in emulsifying ointment BNF emc Clotrimazole 1st line GREEN OTC fungal skin infections 1% cream BNF emc Miconazole 2nd line GREEN OTC fungal skin infections BNF emc 2% cream Terbinafine 2nd line GREEN OTC fungal skin infections 1% cream BNF emc 13.10.3 Antiviral preparations Aciclovir 1st line GREEN OTC 5% cream (see also section 5.3.2.1) BNF emc 13.10.4 Parasiticidal preparations NICE CKS: Head lice NICE CKS: Pubic lice **NICE CKS: Scabies** Ivermectin (1) MMC BNF emc® Malathion 0.5% aqueous solution BNF emc Permethrin GREEN BNF emc MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition. 13.10.5 Preparations for minor cuts & abrasions **Brulidine RESTRICTED** Theatres only 0.15% w/w cream emc_® Preparations for boils Magnesium sulfate naste RP BNF emc® Skin tissue adhesive Histoacryl® **RESTRICTED** Theatres only

0.5mL skin adhesive

BNF emc®





13.13 Topical circulatory preparations Topical circulatory preparations Heparinoid GMMG	
, , ,	
Heparinoid	
Hirudoid® 0.3% cream: 0.3% gel	

13.14 Miscellaneous preparations				Gм <mark>₩</mark> мG	
8-Methoxypsoralen				RESTRICTED Dermatology Consultants only	,
10mg tablets		MMC	emc _®		
Fumaric acid esters ①				RESTRICTED Dermatology Consultants only	,
Fumaderm® tablets		MMC	emc _®		
Glucarpidase ①		[8]	N/F	RESTRICTED 2 nd line rescue therapy	
Voraxaze ® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4)	PbR X	MMC 🔠	NF emc	E	NHS England
Hyaluronic acid with lidocaine 0				RESTRICTED vocal cord paralysis	
Juvederm® / Belotero® injection		MMC	emc⊛		

WIFT FORMULATY VIO.7 (July 2023)	Skiii
Non-Formulary Items	GM <mark>M</mark> MG
Bio-oil®	
(DNP) OTC	in line with GMMMG
Cradle cap (self-limiting) (DNP) OTC	in line with GMMMG / NHSE
E.g. almond oil, olive oil, cradle cap shampoos	
Dandruff (DNP) OTC	in line with GMMMG / NHSE
Deoxycholic acid	
(DNP)	in line with GMMMG
Diprobase®	DISCONTINUED
ream; ointment BNF (er	September 2021
mollient bath and shower preparations without antimicrobials	
(DNP) OTC	in line with GMMMG
excessive sweating (hyperhidrosis)	in line with CMMMC / NUCE
(DNP) OTC	in line with GMMMG / NHSE
luminium chloride 20% solutions (e.g. Driclor, Anhydrol Forte)	
lead lice	in line with GMMMG / NHSE
(DNP) OTC	
imeticone, malathion, cyclomethicone, permethrin shampoos and liquids. "Bug buster" kits, nit combs.	
lydrocortisone (DNP)	in line with GMMMG
5% ointment; 2.5% cream and ointment Novuriding in dimethyl sulfavide	nc⊚
loxuridine in dimethyl sulfoxide (DNP)	in line with GMMMG
erpid® topical solution	
nfrequent cold sores of the lip (DNP) OTC	in line with GMMMG / NHSE
ciclovir cream, Zovirax® cold sore cream ngenol mebutate	MUTUSSAMA
igenor messatate	WITHDRAWN February 2020
icato® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities)	r obradily 2020
HRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato ▼): suspension of the licence due to risk of skin malignancy	
HRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato ▼): increased incidence of skin tumours seen in some clinica	l studies
anolin cream (DNP) OTC	in line with GMMMG
g. Lansinoh HPA BNF @r	nc⊚
fild acne (DNP)	in line with GMMMG / NHSE
fild dry skin or irritant dermatitis	in line with GMMMG / NHSE
finocycline (DNP)	in line with GMMMG
SINITE CONTROL OF THE	
blets; capsules; M/R capsules finor burns and scalds	nc ⊕
(DNP)	in line with GMMMG / NHSE
linoxidil	
(DNP)	in line with GMMMG / NHSE
utaneous foam BNF @r	nco
appy rash (DNP) OTC	in line with GMMMG / NHSE
.g. barrier preparations (Sudocrem®, Metanium®)	
otassium hydroxide	in line with GMMMG
(DNP)	in the with Gwiming
IolluDab® 5% topical solution	
Proflavine cream, BPC	DISCONTINUED July 2018
1% cream er	nc _o

Skin

Ringworm / Athlete's foot (DNP) OTC	in line with GMMMG / NHSE
Topical preparations containing miconazole, clotrimazole, etc	
Silk garments (DNP)	in line with GMMMG / NHSE
including Dermasilk®, Dreamskin®, Skinnies Silk®	
Sun protection (DNP) OTC	in line with GMMMG / NHSE
Sunburn due to excessive sun exposure (DNP) OTC	in line with GMMMG / NHSE
E.g. emollients, oral and topical antihistamines, analgesics	
Warts and verrucae (ONP) OTC	in line with GMMMG / NHSE
Salicylic acid-containing products glutaraldehyde	

Section 14: Immunological products & vaccines | Supported by the formulary (click here)



14.4 Vaccines & antisera

Bacillus Calmette-Guérin (BCG) vaccines

Botulism antitoxin

COVID-19 vaccine

Diphtheria vaccines (children under 10yrs old)

Diphtheria vaccines (children over 10yrs old & adults)

Haemophilus type B conjugate vaccine

Hepatitis A vaccine

Hepatitis B vaccine

Human papilloma virus vaccine

Influenza vaccine

Measles, Mumps & Rubella (MMR) vaccine

Meningococcal vaccines

Pneumococcal vaccines

Poliomyelitis vaccines

Rabies vaccines

Respiratory syncytial virus (RSV) vaccine

Tetanus vaccines

Typhoid vaccines

Varicella-zoster vaccines

14.5 Immunoglobulins

14.5.1 Normal immunoglobulin

14.5.2 Disease-specific immunoglobulins

14.5.3 Anti-D (Rh₀) immunoglobulin

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin

Immunoglobulin follow up form

Immunoglobulin Prescribing and Administration Guidelines

Immunoglobulin Prescribing Flow Chart

Immunoglobulin request form

National Demand Programme for Immunoglobulin - Clinical Info

Non-formulary Conversion Table

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMMG Formulary

Formulary Homepage

Chapter 14: Immunological products & vaccines

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


Other Links

National Immunoglobulin Database

DH: Clinical guidelines for immunoglobulin use (2nd edition update)

Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera	GMMG
MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed	Tuberculosis: the Green Book, ch.32
Bacillus Calmette-Guérin (BCG) vaccines Bacillus Calmette-Guérin (BCG) vaccine	Tuberculosis: the Green Book, ch.32
Bacillus Gailliette-Guerill (BCG) vaccille	
SANG to make	
BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))	emc
SINE Consider	
	<u>emc</u> ⊚
Botulism antitoxin	
Botulism antitoxin	RESTRICTED
E NATA	Emergencies only
	emco
COVID-19 vaccine	Covid19: the Green Book, ch.14a
Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)	12 years of age and older
	12 years of age and older
Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)	emc pending availability of XBB1.5
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)	12 years of age and older
	12 years or age and older
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	emc
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)	
	5 to 11 year olds
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	emco
MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023	<u></u>
MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023	
MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023	
MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022	
MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022	
MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022 MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022	
MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022	
MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022	
MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022	
MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022	
MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022	
MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022	
MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022 MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022	
MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021	
MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021	
MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021	
MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021	
MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021	
MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021 MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021	
MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021	
MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021	
MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current a	advice
MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19	
Diphtheria vaccines (children under 10yrs old)	Diptheria: the Green Book, ch.15
Infanrix hexa®	
	emc _®
Infanrix-IPV®	
injection BNF	emc
Repevax®	
injection BNF	emc
Diphtheria vaccines (children over 10yrs old & adults)	Diptheria: the Green Book, ch.15
Revaxis ®	
injection BNF	emc



14.5 Immunoglobulins



- **1.)** All Immunoglobulin requests should follow NHSE Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England (2024).
- **2.)** MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.
- 3.) All immunoglobulin use MUST be recorded on the National Immunoglobulin Database.

14.5.1 Normal immunoglobulin RED	(for ITP & home treatment programmes)	G^MMG
For intramuscular use		
Normal immunoglobulin injection	EVN.	RESTRICTED Specialist use only
injection For subcutaneous use	PbR X BNF emco	
Normal immunoglobulin injection		0507010750
RED EE	CON (RESTRICTED Specialist use only
injection	PbR X MMC BNF emc	
For intravenous use		
Human normal immunoglobulin		RESTRICTED Specialist use only
injection	PBRX MMC BNF EMC	- V -
14.5.2 Disease-specific immunoglobulins		G⋈ <mark>M</mark> MG
Hepatitis B immunoglobulin		
Hepatitis B immunoglobulin	E>M.€	RESTRICTED Not Stocked
injection	BNF emco	
Rabies immunoglobulin		
Rabies immunoglobulin	R) NIE	RESTRICTED Virology advice only
injection	MMC BNF emc	
Tetanus immunoglobulin		
Tetanus immunoglobulin	BNF emco	
Varicella-Zoster immunoglobulin		
Varicella-Zoster immunoglobulin	ENAM	RESTRICTED Not Stocked
injection	BNF emco	
Cytomegalovirus (CMV) immunoglobulin		
Human normal immunoglobulin (CMV)		RESTRICTED Specialist use only
injection 14.5.3 Anti-D (Rh ₀) immunoglobulin	MMC BNF emco	GM <mark>₩</mark> MG
		GMMMG
Anti-D (Rh ₀) immunoglobulin		
injection	NICE MMC BNF @mc	

Non-Formulary Items	GM <mark>™</mark> MG	
AstraZeneca COVID-19 vaccine	DISCONTINUED	
	May 2024	
√axzevria® injection	MMC BNF emc	
Moderna Biotech COVID-19 vaccine	DISCONTINUED	
	DISCONTINUED	
Spikevax® injection	MMC BNF emco	
Novavax COVID-19 vaccine		
	PAUSED by JCVI	
V <i>uvaxovid</i> ® injection	MMC BNF emco	
Pediacel®	REPLACED by	
· • • • • • • • • • • • • • • • • • • •	Infanrix hexa®	
	to children	
njection	BNF emco	
Infanrix-IPV+Hib®	REPLACED by	
	Infanrix hexa®	
injection	BNF EMC	

Section 15: Anaesthesia

Supported by the formulary (click here)



15.1 General anaesthesia

15.1.1 Intravenous anaesthetics

15.1.2 Inhalational anaesthetics

15.1.3 Antimuscarinic drugs

15.1.4 Sedative & analgesic post-operative drugs

15.1.4.1 Benzodiazepines

15.1.4.2 Non-opioid analgesics

15.1.4.3 Opioid analgesics

15.1.4.4 Other drugs for sedation

15.1.5 Neuromuscular blocking drugs

Non-depolarising neuromuscular blocking drugs

Depolarising neuromuscular blocking drugs

15.1.6 Drugs for reversal of neuromuscular blockade

Anticholinesterases

Other drugs for reversal of neuromuscular blockade

15.1.7 Antagonists for central & respiratory depression

15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

Lidocaine

Bupivacaine

Levobupivacaine

Prilocaine

Ropivacaine

Tetracaine

Local Anaesthetic Toxicity

Other agents

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Paediatric Anaesthesia Website

Children's Pain Management Website

PICU Emergency Drugs Calculator

Non-formulary Conversion Table

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

GMMMG Formulary

Formulary Homepage


Chapter 15: Anaesthesia (ON HOLD)

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

5.1.1 Intravenous anaesthetics		
tomidate		
ioniauto		
	(5XNIP) for children	
ection	BNF emc	
etamine RED 6		
	ENTS to continue	
ection	BNF emc	
Propofol		
jection; infusion	MMC BNF emc	
hiopental sodium		
njection	BNF emco	
5.1.2 Inhalational anaesthetics		
/olatile liquid anaesthetics		
Desflurane		RESTRICTED
estici dile		
	Existing the considerer	Theatres only
naesthetic agent	MMC BNF emc	
soflurane		
naesthetic agent	MMC BNF emc	
Methoxyflurane		RESTRICTED
		ED only
enthrox® inhalation vapour	MMC BNF emc	
evoflurane		
	ionni-	
naesthetic agent	BNF emco	
litrous oxide	BNF CIICO	
litrous oxide		
illious oxide		
	ISINIF Karahidran	
	BNF emc	
Nitrous oxide 50% & oxygen 50%		
Entonox®	BNF emc	
5.1.3 Antimuscarinic drugs		
Atropine sulfate		Adults 600microgram/1mL
		I.M. or I.V.
00microgram/1mL injection	BNF emco	
Blycopyrronium bromide		
	I EX NII E	Adults 200-400microgram I.V.
00micrograms/1mL; 600micrograms/3mL injection	to children	
lyoscine hydrobromide	BNF @MC®	
yoscine nyurobronnue		
	(BS) XVIII P for children	
00microgram/mL injection	BNF emco	
5.1.4 Sedative & analgesic post-operative drugs		
5.1.4.1 Benzodiazepines		NICE CG112
liazepam		
GREEN &	ENT	
blets; liquid; injection; rectal tube (see also sections 4.1.2; 4.8.2 & 10.2.2)	BNF emco	
orazepam		
•	120N1=	
blets; injection (see also sections 4.1.2 & 4.8.2)	To californ	
Aidazolam	BNF emc	
GREEN 🚵		
	ES INC.	
romucosal solution; injection; infusion (see also section 4.8.2)	BNF emc	
emazepam GREEN		
<u>CD</u>	ES RIFE	
ablets; oral solution (see also section 4.1.1)	BNF emc	
5.1.4.2 Non-opioid analgesics		
-	BNN116	
5.1.4.2 Non-opioid analgesics (etorolac trometamol	MMC BNE CMC	
Setorolac trometamol	MMC BNF emc	PECTRICTER
etorolac trometamol	MMC BNF emc	RESTRICTED Theatres only - acute poston, pai
Setorolac trometamol ejection Parecoxib		RESTRICTED Theatres only - acute postop. pai
Setorolac trometamol	MMC BNF emc	

15.1.4.3 Opioid analgesics		
Alfentanil		
<u>A</u>	Equipment them	
	TSURIT for children	
njection	BNF emc	
Fentanyl		
<u>&</u>		
njection (see also section 4.7.2)	for children	
Remifentanil	BNF emc	
		RESTRICTED
<u>&</u>	(B) X) P	Specialist use only
njection	MMC BNF emc	
5.1.4.4 Other drugs for sedation	TOTAL CALLS	
Dexmedetomidine hydrochloride		RESTRICTED
		Specialist use only
ıfusion	MMC BNF emc	
5.1.5 Neuromuscular blocking drugs	1011019	
lon-depolarising neuromuscular blocking drugs		
tracurium besilate		
	ELNIS	
jection	BNF emco	
Cisatracurium	BNF GIIC	PECTRICIES
noun aout i uni		RESTRICTED
	ENAIS	Consultant only
njection	MMC BNF emc	
, Mivacurium		
	·	
	Log N.V.F	
jection	BNF emc	
Rocuronium bromide		
jection	or children	
/ecuronium bromide	BNF emc	
recuronium promide		
	ERIF	
njection	BNF emco	
Depolarising neuromuscular blocking drugs		
Suxamethonium chloride		
Suxamethomam chioride		
	LES RUF for children	
njection	BNF emc	
15.1.6 Drugs for reversal of neuromuscular blockade		
Anticholinesterases		
Neostigmine metilsulfate		
toodigiiiilo iilotiiodiidto		
	(B) K) (F) for children	
njection (see also section 10.2.1)	BNF emc	
leostigmine metilsulfate with glycopyrronium bromide		
	restable.	
	ISSN III F	
,	BNF emco	
•	BNF emco	
Other drugs for reversal of neuromuscular blockade	BNF emc	RESTRICTED - Consultant
Other drugs for reversal of neuromuscular blockade	BNF emc	
Other drugs for reversal of neuromuscular blockade Sugammadex		(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex	BNF emco	
Other drugs for reversal of neuromuscular blockade sugammadex		(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade sugammadex ridion ® injection 5.1.7 Antagonists for central & respiratory depression		(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Aridion ® injection 5.1.7 Antagonists for central & respiratory depression		(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Aridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride		(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Dispection (see also section 3.5.1)	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride njection (see also section 3.5.1)	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Aridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Dispection (see also section 3.5.1) Flumazenil	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Aridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Disjection (see also section 3.5.1) Flumazenil	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride njection (see also section 3.5.1) Flumazenil	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride njection (see also section 3.5.1) Flumazenil	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride	MMC BNF emc	(Emergency) use in Theatres only
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion (8) injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride	MMC BNF emc	(Emergency) use in Theatres only Complete Trust incident & audit forms
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion (8) injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride	MMC BNF emc	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms
Injection Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride	MMC BNF emc	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Nyxoid ® 1.8mg nasal spray	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Nyxoid ® 1.8mg nasal spray 15.1.8 Drugs for malignant hyperthermia	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Doxapram hydrochloride Injection (see also section 3.5.1) Flumazenil Injection Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride 1.8mg nasal spray 15.1.8 Drugs for malignant hyperthermia Dantrolene sodium	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED
Other drugs for reversal of neuromuscular blockade Sugammadex Bridion ® injection 15.1.7 Antagonists for central & respiratory depression Ooxapram hydrochloride njection (see also section 3.5.1) Flumazenil njection Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone hydrochloride Naloxone fydrochloride Naloxone fydrochloride	BNF emco	(Emergency) use in Theatres only Complete Trust incident & audit forms RESTRICTED



Section 16: Miscellaneous



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents
- 16.1.4 Hydrogen / Methane breath tests
- 16.1.5 Catheter Lock Solution

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

16.1 Organ Perfusion fluids			
16.1.1 Cardiac perfusion fluids			
Aspartate / Glutamate solution			
·			
100mL	MMC		
Bretschneiders Histidine-Trytophan-Ketoglutarate (HTK)	1011010		
Custodiol Cardioplegia® solution (1000mL)	MMC	emc⊛	
Cardioplegia in Ringer's solution	101101	<u> </u>	
1000mL	MMC	emc _®	
Cardioplegic ULTH Formula A 00			
500mL	MMC		
Cardioplegic ULTH Formula B 0	1011010		
500mL	MMC		
Sterile Concentrate for Cardioplegia infusion	1011019		
· · ·			
20mL	MMC	emc _®	
16.1.2 Kidney / Pancreas / Liver perfusion fluids	100000	<u></u>	
Cold Storage Solution (UW solution)			
Belzer UW® (1000mL)	MMC		
Kidney Perfusion Fluid			
Soltran® (1000mL)	MMC		
Lung Perfusion solution			
Perfadex® (1000mL)	MMC		
Machine Perfusion solution			
Belzer MPS® UW machine perfusion solution (1000mL)	MMC		
16.1.3 Contrast Agents			
Gadobutrol			
Gadovist ® (1.0mmol/mL) injection	MMC	emc⊕	
Gadoteric acid			
Dotarem ® (0.5mmol/mL) injection	MMC	<u>emc</u> ⊚	
Gadoxetic acid			
Primovist® (0.25mmol/mL) injection Perflutren	MMC	<u>emc</u>	
remunen			
1. marinity @ (4FOmina-lites-lead Visited animals the second	8888		
Luminity ® (150microlitres/mL) lipid microspheres for injection Sulphur hexafluoride	MMC	<u>emc</u> ⊚	
Outpridi rickandondo			
Canalina () / Omigrality / Mal \ inication	AAAA	ama a	
SonoVue ® (8microlitre/mL) injection 16.1.4 Hydrogen / Methane breath tests	MMC	emc⊕	
Fructose, Glucose, Lactose and Lactulose U			RESTRICTED Gastro. only in line with
		≢ ESPGHAN	ECDCHAN avidalinas
powder	MMC	emc	•
16.1.5 Catheter Locking Solution	701101	CITICO	
Tetrasodium ethylene diamine tetra acetic acid (EDTA)			
KiteLock™ 4% sterile catheter lock solution	MMC	<u>emc</u> ⊛	
Trisodium citrate 30%			
Citra-Lock™ 30%	MMC	emc⊛	